• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Nukkleus Inc.

    5/23/25 4:37:37 PM ET
    $NUKK
    Professional Services
    Consumer Discretionary
    Get the next $NUKK alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-Q

     

    ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the quarterly period ended March 31, 2025

     

    OR

     

    ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from __________ to __________

     

    Commission file number: 001-39341

     

    Nukkleus Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   38-3912845
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    575 Fifth Ave, 14th Floor, New York, New York 10017

    (Address of principal executive offices, including zip code)

     

    212-791-4663

    (Registrant’s telephone number, including area code)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   NUKK   The Nasdaq Stock Market LLC
             
    Warrants, each warrant exercisable for one Share of Common Stock for $92.00 per share   NUKKW   The Nasdaq Stock Market LLC

     

    Securities registered under Section 12(g) of the Exchange Act: None

     

    Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐    No ☒

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer  ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

     

    State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date.

     

    Class   Outstanding May 22, 2025
    Common Stock, $0.0001 par value per share   5,360,844 shares

     

     

     

     

     

     

    NUKKLEUS INC.

    FORM 10-Q

    March 31, 2025

     

    TABLE OF CONTENTS

     

            Page No.
    PART I - FINANCIAL INFORMATION    
    Item 1.   Interim Financial Statements   1
        Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024   1
        Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2025 and 2024   2
        Unaudited Condensed Consolidated Statements of Changes in Stockholders’ (Deficit) Equity for the Three Months Ended March 31, 2025 and 2024   3
        Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024   5
        Notes to Unaudited Condensed Consolidated Financial Statements   6
             
    Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations   28
    Item 3.   Quantitative and Qualitative Disclosures About Market Risk   35
    Item 4.   Controls and Procedures   35
    Item 5.   Other   36
             
    PART II - OTHER INFORMATION    
    Item 1.   Legal Proceedings   37
    Item 1A.   Risk Factors   37
    Item 2.   Recent Sales of Unregistered Securities   37
    Item 3.   Defaults Upon Senior Securities   37
    Item 4.   Mine Safety Disclosures   37
    Item 5.   Other Information   37
    Item 6.   Exhibits   38
    Signatures   40

     

    i

     

     

    FORWARD LOOKING STATEMENTS

     

    This report contains forward-looking statements that involve a number of risks and uncertainties which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Although our forward-looking statements reflect the good faith judgment of our management, these statements can be based only on facts and factors of which we are currently aware. Consequently, forward-looking statements are inherently subject to risks and uncertainties. Actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.

     

    Forward-looking statements can be identified by the use of forward-looking words such as “may,” “will,” “should,” “anticipate,” “believe,” “expect,” “plan,” “future,” “intend,” “could,” “estimate,” “predict,” “hope,” “potential,” “continue,” or the negative of these terms or other similar expressions. These statements include, but are not limited to, statements under the captions “Risk Factors,” “Management’s Discussion and Analysis or Plan of Operation” and “Description of Business,” as well as other sections in this report. Such forward-looking statements are based on our management’s current plans and expectations and are subject to risks, uncertainties and changes in plans that may cause actual results to differ materially from those anticipated in the forward-looking statements. You should be aware that, as a result of any of these factors materializing, the trading price of our common stock may decline. These factors include, but are not limited to, the following:

     

    ●the availability and adequacy of capital to support and grow our business;

     

    ●economic, competitive, business and other conditions in our local and regional markets;

     

    ●actions taken or not taken by others, including competitors, as well as legislative, regulatory, judicial and other governmental authorities;

     

    ●competition in our industry;

     

    ●changes in our business and growth strategy, capital improvements or development plans;

     

    ●the availability of additional capital to support development; and

     

    ●other factors discussed elsewhere in this annual report.

     

    The cautionary statements made in this quarterly report are intended to be applicable to all related forward-looking statements wherever they may appear in this report.

     

    We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We undertake no obligation to publicly update any forward looking-statements, whether as a result of new information, future events or otherwise.

     

    All references in this Form 10-Q that refer to the “Company”, “Nukkleus”, “we,” “us” or “our” refer to Nukkleus Inc. and its consolidated subsidiaries.

     

    ii

     

     

    PART I - FINANCIAL INFORMATION

     

    Item 1. Interim Financial Statements.

     

    NUKKLEUS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

     

       March 31,   December 31, 
       2025   2024 
       (Unaudited)   (Audited) 
    ASSETS        
             
    CURRENT ASSETS:        
    Cash and cash equivalents  $4,462,916   $6,897,697 
    Advances - related party   1,800,000    1,000,000 
    Other current assets   72,817    107,648 
    Current assets from discontinued operations   2,127,120    1,089,052 
               
    TOTAL CURRENT ASSETS   8,462,853    9,094,397 
               
    NON-CURRENT ASSETS:          
    Right-of-use asset, operating lease   117,406    
    -
     
    Fixed assets, net   9,922    - 
    Other assets from discontinued operations   11,646    14,887 
               
    TOTAL NON-CURRENT ASSETS   138,974    14,887 
               
    TOTAL ASSETS  $8,601,827   $9,109,284 
               
    LIABILITIES AND STOCKHOLDERS’ DEFICIT          
               
    CURRENT LIABILITIES:          
    Accounts payable  $18,341   $69,600 
    Operating lease liability, current portion   51,214    - 
    Convertible notes payable, net   831,623    706,354 
    Note payable, net   74,600    64,399 
    Due to affiliates   45,078    42,471 
    Loans payable - related parties, current   619,440    619,440 
    Accrued expenses and other current liabilities   916,949    1,167,315 
    Stock purchase warrant liabilities   57,436,424    164,770,525 
    Derivative liability   280,340    847,753 
    Current liabilities from discontinued operations   4,435,236    3,162,509 
               
    TOTAL CURRENT LIABILITIES   64,709,245    171,450,366 
               
    NON-CURRENT LIABILITIES:          
    Operating lease liability, net of current portion   66,192    - 
    Loan payable - related parties, net of current portion   947,548    947,548 
    Interest payable - related parties, net of current portion   77,952    44,111 
    Non-current liabilities from discontinued operations   17,906    17,368 
               
    TOTAL NON-CURRENT LIABILITIES   1,109,598    1,009,027 
               
    TOTAL LIABILITIES   65,818,843    172,459,393 
               
    COMMITMENTS AND CONTINGENCIES - (Note 12)   
     
        
     
     
               
    STOCKHOLDERS’ DEFICIT:          
    Preferred stock ($0.0001 par value; 15,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2025 and December 31, 2024)   
    -
        
    -
     
    Common stock ($0.0001 par value; 150,000,000 shares authorized; 5,013,863 and 4,930,531 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively)   501    493 
    Additional paid-in capital   40,993,300    37,759,589 
    Accumulated deficit   (98,117,604)   (201,075,743)
    Accumulated other comprehensive (loss) income   (93,213)   (34,448)
               
    TOTAL STOCKHOLDERS’ DEFICIT   (57,217,016)   (163,350,109)
               
    TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $8,601,827   $9,109,284 

     

    The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

    1

     

     

    NUKKLEUS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited)

      

       For the Three Months Ended
    March 31,
     
       2025   2024 
    REVENUES        
    Revenue - general support services - related party  $
    -
       $
    -
     
    Revenue - financial services   
    -
        
    -
     
    Total revenues   
    -
        
    -
     
               
    COSTS OF REVENUES          
    Cost of revenue - general support services - related party   
    -
        
    -
     
    Cost of revenue - financial services   
    -
        
    -
     
    Total costs of revenues   
    -
        
    -
     
               
    GROSS PROFIT (LOSS)          
    Gross profit - general support services - related party   
    -
        
    -
     
    Gross profit (loss) - financial services   
    -
        
    -
     
    Total gross profit (loss)   
    -
        
    -
     
               
    OPERATING EXPENSES:          
    Professional fees   954,142    1,831,747 
    Compensation and related benefits   63,510    30,000 
    Other general and administrative   489,455    223,429 
               
    Total operating expenses   1,507,107    2,085,176 
               
    LOSS FROM OPERATIONS   (1,507,107)   (2,085,176)
               
    OTHER (EXPENSE) INCOME:          
    Interest expense   (164,576)   
    -
     
    Interest expense - related parties   (33,841)   (10,025)
    Change in fair value - convertible note embedded derivative   567,413    
    -
     
    Change in fair value - stock purchase warrant liabilities   104,278,287    
    -
     
    Other income (expense)   718    
    -
     
               
    Total other income (expense), net   104,648,001    (10,025)
               
    INCOME (LOSS) BEFORE INCOME TAXES   103,140,894    (2,095,201)
               
    INCOME TAXES   
    -
        
    -
     
               
    NET INCOME (LOSS) FROM CONTINUING OPERATIONS   103,140,894    (2,095,201)
    NET LOSS FROM DISCONTINUED OPERATIONS   (182,755)   (334,216)
    NET INCOME (LOSS)  $102,958,139   $(2,429,417)
               
    COMPREHENSIVE LOSS:          
    NET INCOME (LOSS)  $102,958,139   $(2,429,417)
    OTHER COMPREHENSIVE (LOSS) INCOME          
    Unrealized foreign currency translation (loss) gain   (58,765)   26,582 
    COMPREHENSIVE INCOME (LOSS)  $102,899,374   $(2,402,835)
               
    NET INCOME (LOSS) PER COMMON SHARE:          
    Continuing operations, basic   20.80   $(1.19)
    Discontinued operations, basic   (0.04)   (0.19)
    Basic  $20.76   $(1.38)
               
    Continuing operations, diluted   18.19    
    -
     
    Discontinued operations, diluted   (0.04)   
    -
     
    Diluted  $18.15    
    -
     
               
    WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:          
    Basic   4,959,516    1,754,449 
    Diluted   5,671,702    
    -
     

     

    The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

     

    2

     

     

    NUKKLEUS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

    For the Three Months Ended March 31, 2025

    (Unaudited)

     

                               Accumulated     
       Preferred Stock   Common Stock   Additional       Other   Total 
       Number of       Number of       Paid-in   Accumulated   Comprehensive   Stockholders’ 
       Shares   Amount   Shares   Amount   Capital   Deficit   Income (Loss)   Deficit 
                                     
    Balance as of December 31, 2024   
       -
       $
          -
        4,930,531   $493    37,759,589    (201,075,743)   (34,448)   (163,350,109)
                                             
    Issuance of common stock from exercise of pre-funded warrants   -    
    -
        83,332   $8   $3,055,806    
    -
        
    -
        3,055,814 
                                             
    Stock-based compensation   -    
    -
        -    
    -
       $177,905    
    -
        
    -
        177,905 
                                             
    Net income for the three months ending March 31, 2025   -    
    -
        -    -    -    102,958,139    -    102,958,139 
                                             
    Foreign currency translation adjustment   -    
    -
        -    
    -
        
    -
        
    -
        (58,765)   (58,765)
                                             
    Balance as of March 31, 2025   
    -
        
    -
        5,013,863    501    40,993,300    (98,117,604)   (93,213)   (57,217,016)

     

    The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

     

    3

     

     

    NUKKLEUS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

    For the Three Months Ended March 31, 2024

    (Unaudited)

     

                               Accumulated     
       Preferred Stock   Common Stock   Additional       Other   Total 
       Number of       Number of       Paid-in   Accumulated   Comprehensive   Stockholders’ 
       Shares   Amount   Shares   Amount   Capital   Deficit   Income (Loss)   Deficit 
                                     
    Balance as of December 31, 2023   
     -
       $
         -
        1,737,464   $174    35,025,036    (44,940,441)   (31,354)   (9,946,585)
                                             
    Stock-based compensation   -    
    -
        -    
    -
        74,668    
    -
        
    -
        74,668 
                                             
    Issuance of common stock as compensation for services   -    
    -
        25,338    3    749,997    
    -
        
    -
        750,000 
                                             
    Net loss for the three months ending March 31, 2024   -    
    -
        -    
    -
        
    -
        (2,429,417)   
    -
        (2,429,417)
                                             
    Foreign currency translation adjustment   -    
    -
        -    
    -
        
    -
        
    -
        26,582    26,582 
                                             
    Balance as of March 31, 2024   
    -
       $
    -
        1,762,802   $177    35,849,701    (47,369,858)   (4,772)   (11,524,752)

     

    The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

     

    4

     

     

    NUKKLEUS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

     

       Three months ended 
       March 31, 
       2025   2024 
    CASH FLOWS FROM OPERATING ACTIVITIES:        
    Net income (loss)   102,958,139    (2,429,417)
    Net loss from discontinued operations   (182,755)   (334,216)
    Net income (loss) from continuing operations  $103,140,894   $(2,095,201)
    Adjustments to reconcile net loss to net cash used in operating activities:          
    Amortization of debt discount   135,470    
    -
     
    Depreciation expense   299    
    -
     
    Stock-based compensation   177,905    74,668 
    Change in fair value - convertible note embedded derivative   (567,413)   
    -
     
    Change in fair value - stock purchase warrant liabilities   (104,278,287)   
    -
     
    Changes in operating assets and liabilities:          
    Other current assets   34,831    (6,605)
    Accounts payable   (51,259)   
    -
     
    Due to affiliates   2,607    
    -
     
    Interest payable - related parties   33,841    10,024 
    Accrued liabilities and other payables   (250,366)   1,842,215 
               
    Net cash used in operating activities from continuing operations   (1,621,478)   (174,899)
    Net cash provided by (used in) operating activities from discontinued operations   279,964    (947,810)
    NET CASH USED IN OPERATING ACTIVITIES   (1,341,514)   (1,122,709)
               
    CASH FLOWS FROM INVESTING ACTIVITIES:          
    Purchase of computer equipment   (10,221)   
    -
     
    Advance to target of planned acquisition   (800,000)   
    -
     
               
    Net cash (used in) provided by investing activities from continuing operations   (810,221)   
    -
     
    Net cash (used in) provided by investing activities from discontinued operations   
    -
        
    -
     
    NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES   (810,221)   
    -
     
               
    CASH FLOWS FROM FINANCING ACTIVITIES          
    Proceeds from loan payable - related parties   
    -
        293,000 
               
    Net cash provided by financing activities from continuing operations   
    -
        293,000 
    Net cash provided by financing activities from discontinued operations   
    -
        627,729 
    NET CASH PROVIDED BY FINANCING ACTIVITIES   
    -
        920,729 
               
    EFFECT OF EXCHANGE RATE ON CASH FROM CONTINUING OPERATIONS   (3,082)   
    -
     
    EFFECT OF EXCHANGE RATE ON CASH FROM DISCONTINUED OPERATIONS   35,464    (10,410)
               
    Net change in cash, including cash from discontinued operations   (2,119,353)   (212,390)
               
    Cash, including cash from discontinued operations - beginning of period   7,857,641    863,610 
               
    Cash, including cash from discontinued operations - end of period   5,738,288    651,220 
               
    Less cash from discontinued operations   1,275,372    645,235 
               
    Cash from continuing operations, end of period  $4,462,916   $5,985 
               
    NON-CASH INVESTING AND FINANCING ACTIVITIES:          
    Fair value of pre-funded warrants exercised  $3,055,814   $
    -
     
    Issuance of common stock to settle accrued expenses and other current liabilities  $
    -
       $750,000 

     

    The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

     

    5

     

     

    NUKKLEUS INC. AND SUBSIDIARIES

    NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

    (Unaudited)

     

    NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

     

    Nukkleus Inc. and its wholly owned subsidiaries, were financial technology companies that were previously focused on providing software, technology solutions, customer sales and marketing, and risk management technology hardware and software solutions packages for the worldwide retail foreign exchange (“FX”) trading industry and payment services from one fiat currency to another or to digital assets.

     

    In January 2024, Nukkleus Inc and its wholly owned subsidiaries ceased its general support service operations, terminating the existing customer and supplier contracts with a related party, and shifted its focus to the payment services operations. In November 2024, Nukkleus Inc. entered into a Settlement Agreement and Release (the “Settlement Agreement”) with a shareholder and one of our subsidiaries to sell the subsidiary that operates the payment services operations to the shareholder in consideration of GBP 1,000 (approximately $1,294 at March 31, 2025).

     

    In December 2024, Nukkleus Inc entered into a Securities Purchase Agreement and Call Option (the “Star Agreement”) with Star 26 Capital Inc. (“Star”), the shareholders of Star (“Star Equity Holders”) and an officer of Nukkleus, acting in his capacity as the representative of the Star Equity Holders, to acquire a controlling 51% interest in Star, an Israeli corporation engaged as a supplier of generators for “iron dome” launchers and other defense products. As a result of the Settlement Agreement and subject to the closing of the acquisition of Star, Nukkleus, Inc.’s business will be focused on the defense sector.

     

    On February 14, 2025, the Board of Directors of Nukkleus Inc. and its wholly owned subsidiaries approved a change in the Company’s fiscal year end from September 30 to December 31, effective for the fiscal year beginning January 1, 2024. This change results in a transition period from October 1, 2024, to December 31, 2024.

     

    The decision to change the fiscal year end was made to align the Company’s financial reporting with the calendar year, which is expected to enhance operational efficiency, improve comparability with industry peers, and better serve the needs of shareholders. Further, the Company intends to align its fiscal year with Star.

     

    Basis of Presentation and Principles of Consolidation: On December 22, 2023 (the “Closing Date”), Brilliant Acquisition Corp (“Brilliant”) entered into a business combination agreement (the “Business Combination”) with each of the shareholders of Nukkleus Inc. (“Old Nukk”). Pursuant to the Business Combination, Brilliant acquired all of the issued and outstanding shares of common stock from the Old Nukk shareholders.

     

    On the Closing Date, and in connection with the closing of the Business Combination, Brilliant changed its name to Nukkleus Inc (the “Company”) and the Company’s common stock began trading on the NASDAQ under the ticker symbol NUKK. Old Nukk was deemed the accounting acquirer in the Business Combination based on an analysis of the criteria outlined in Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”). The determination was primarily based on Old Nukk’s shareholders prior to the Business Combination having a majority of the voting interests in the combined company, Old Nukk’s ability to exert control over the majority of the board of directors of the combined company, and given the board of directors election and retention provisions, Old Nukk’s ability to maintain control of the board of directors on a go-forward basis, Old Nukk’s senior management comprising the senior management of the combined company; and old Nukk’s operations prior to the Business Combination comprise the ongoing operations of the combined company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Old Nukk issuing stock for the net assets of Brilliant, accompanied by a recapitalization. The net assets of Brilliant were stated at historical cost, with no goodwill or other intangible assets recorded.

     

    While Brilliant was the legal acquirer in the Business Combination, because Old Nukk was deemed the accounting acquirer, the historical financial statements of Old Nukk became the historical financial statements of the combined company, upon consummation of the Business Combination. As a result, the financial statements included in this report reflect (i) the historical operating results of Old Nukk prior to the Business Combination; (ii) the combined results of Brilliant and Old Nukk following the closing of the Business Combination; (iii) the assets and liabilities of Old Nukk at their historical cost; and (iv) the Company’s equity structure for all periods presented.

     

    6

     

     

    Effective October 24, 2024, the Company amended its amended and restated certificate of incorporation to implement a one-for-eight reverse stock split of its common stock (the “2024 Reverse Stock Split”) and increased the number of authorized shares of the Company’s common stock from 40,000,000 to 150,000,000 (see Note 8).

     

    In accordance with guidance applicable to these circumstances, the equity structure has been restated in all comparative periods to give effect to the number of shares of the Company’s common stock, $0.0001 par value per share, issued to Old Nukk shareholders during the Business Combination and the 2024 Reverse Stock Split. Accordingly, the disclosure of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the Business Combination and 2024 Reverse Stock Split for all periods presented.

     

    The accompanying consolidated financial statements include the accounts of Nukkleus Inc, and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. The consolidated financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Any reference in these footnotes to the applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

     

    The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

     

    NOTE 2 – LIQUIDITY AND CAPITAL RESOURCES

     

    The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business. As of March 31, 2025, the Company had cash of approximately $4,463,000, a working capital deficit of approximately $56,246,000 and incurred cash flow used in operating activities from continuing operations of approximately $1,621,000 for the three months ended March 31, 2025. These are indicators of substantial doubt as to the Company’s ability to continue as a going concern for at least one year from issuance of these consolidated financial statements. The Company’s ability to continue as a going concern is dependent upon the management of expenses and ability to obtain necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due, and upon profitable operations.

     

    If additional equity or debt financing is required from outside sources, the Company may not be able to raise it on terms acceptable to it or at all. If the Company is unable to raise additional capital on acceptable terms when needed, its results of operations and financial condition would be materially and adversely affected. Any such financing likely would be dilutive to existing stockholders and could result in significant financial operating covenants that would negatively impact the Company business.

     

    As a result of the above, in connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date these financial statements are available to be issued. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

     

    7

     

     

    NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    Emerging growth company: The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups (“JOBS”) Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as to those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. 

     

    Use of estimates: The preparation of the financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. The Company’s most significant estimates and judgments involve valuation of share-based compensation, valuation of equity-classified stock purchase warrants, valuation of liability-classified stock purchase warrants, valuation of derivative liability, classification of gains and losses on settlement of related party liabilities, the useful lives of long-lived assets, assumptions used in assessing impairment of long-lived assets, and valuation of deferred tax assets and the associated valuation allowances.

     

    Segment reporting: ASC 280, Segment Reporting (“ASC 280”), defines operating segments as components of an enterprise where discrete financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is the chief executive officer, who has ultimate responsibility for the operating performance of the Company and the allocation of resources. The CODM uses operating results as the primary measure to manage the business. As a result of transactions entered into during the three months ended December 31, 2024 (see Note 4), the CODM determined it has one operating segment as of March 31, 2025. Accordingly, the Company has recast the presentation of its reportable segments for the periods presented in these consolidated financial statements. The CODM assesses performance on consolidated operating expenses as the CODM is focused on managing cash flow until a pending disposition (see Note 12) and a pending acquisition (see Note 12) are completed during the second quarter of fiscal year 2025.

     

    Cash and cash equivalents: The Company considers all highly liquid instruments with a maturity date of three months or less at the time of purchase and money market accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2025 and December 31, 2024.

     

    The Company’s cash and cash equivalents are potentially subject to concentration of credit risk. Cash and cash equivalents are primarily placed with financial institutions which are of high credit quality. The Company invests cash and cash equivalents primarily in highly liquid, highly rated instruments which are uninsured. The Company may also have corporate deposit balances with financial institutions which exceed the Federal Deposit Insurance Corporation insurance limit of $250,000. The Company has not experienced losses on these accounts and does not believe it is exposed to any significant credit risk with respect to these accounts.

     

    8

     

     

    Fair value measurements: ASC 820, Fair Value Measurements (“ASC 820”), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows

     

      ● Level 1 – Inputs based on unadjusted quoted market prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

     

      ● Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar instruments in markets that are not active or for which all significant inputs are observable or can be corroborated by observable market data.

     

      ● Level 3 – Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are both unobservable for the asset and liability in the market and significant to the overall fair value measurement.

     

    An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

     

    Assets and liabilities measured at fair value are based on one or more of the following techniques noted in ASC 820:

     

      ● Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

     

      ● Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

     

      ● Income approach: Techniques to convert future amounts to a single present value amount based upon market expectations (including present value techniques, option pricing, and excess earnings models).

     

    The Company believes its valuation methods are appropriate and consistent with other market participants, however the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

     

    The Company’s financial instruments with a carrying value that approximates fair value consist of cash, advances, other current assets, accounts payable, due to affiliates, accrued expenses and other current liabilities, interest payable – related parties, and short-term borrowings due to their liquid or short-term nature or expected settlement dates of these instruments. If these financial instruments were recorded at fair value, they would be based on Level 1 inputs, except for short-term borrowings which would be based on Level 2 and Level 3 inputs, respectively.

     

    The Company’s non-financial assets, such as intangible assets, and financial assets are adjusted to fair value when an impairment charge is recognized. The impairment charge recognized on non-financial assets that consist of acquired intangible assets is based on Level 3 inputs, including a comparison of the Company’s results with expectations and expectation for future profits. The impairment charge recognized for financial assets that consist of investment in privately held equity securities is based on Level 3 inputs, including the global economic environment, adjustments for investment-specific developments and the rights and obligations of the securities the Company holds.

     

    The Company’s financial instruments that are measured at fair value on a recurring basis consist of liability-classified derivative financial instruments, and liability-classified stock purchase warrants (see Note 10).

     

    9

     

     

    Related parties: The Company considers parties to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or significant influence of the same party, such as a family member or relative, shareholder, or a related corporation. The Company reviews the relationships of its vendors, customers, shareholders, and board members to determine whether there are any parties meet the criteria to be considered related. Any party that is deemed to be related to the Company is referred to as an “affiliate” or “related party” in these consolidated financial statements.

     

    Due from affiliates and notes receivable – related parties, net: Due from affiliates and notes receivable – related parties, net are contractual rights to receive cash on demand or on fixed or determinable dates and are recognized as an asset on the consolidated balance sheets. Due from affiliates consist of amounts owed from affiliates of the Company for either services provided to the affiliate or expenses paid by the Company on behalf of the affiliate (see Note 11). Notes receivable – related parties, net consist of advances made to affiliates in exchange for a promissory note from the affiliate (see Note 11).

     

    Other current assets: Other current assets primarily consists of escrow cash and prepaid miscellaneous items. The Company expects all current assets to be collected and/or realized within the next 12 months.

     

    Leases: The Company determines if an arrangement is a lease at inception of the contract. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion in the accompanying consolidated balance sheets.

     

    ROU assets represent the Company’s right to use underlying assets for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the contracts. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.

     

    The Company’s vehicle leases may include transfer rights or options to purchase at the end of the lease that the Company is reasonably certain to exercise. Interest expense is recognized using the effective interest rate method, and the ROU asset is amortized over the useful life of the underlying asset.

     

    Impairment of long-lived assets: In accordance with ASC 360, Impairment or Disposal of Long-Lived Assets (“ASC 360”), the Company reviews the carrying values of long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Based on the existence of one or more indicators of impairment, the Company measures any impairment of long-lived assets using the projected discounted cash flow method at the asset group level. The estimation of future cash flows requires significant management judgment based on the Company’s historical results and anticipated results and is subject to many factors. The discount rate that is commensurate with the risk inherent in the Company’s business model is determined by its management. An impairment loss would be recorded if the Company determined that the carrying value of long-lived assets may not be recoverable. The impairment to be recognized is measured by the amount by which the carrying values of the assets exceed the fair value of the assets.

     

    Note payable, loans payable – related parties, convertible notes payable: Debt issuance costs, including original issue discounts, will be recorded to debt discount, reducing the face amount of the note. Debt issuance costs will be amortized to interest expense over the contractual term of the respective debt obligation using the effective interest method. If a conversion of the underlying debt occurs, a proportionate share of the unamortized discount is immediately expensed.

     

    10

     

     

    The Company evaluates convertible notes payable in accordance with ASC 470, “Debt with Conversion and Other Options” (“ASC 470”) to determine if embedded conversion features present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. Debt issuance costs are allocated proportionately to the debt host and conversion feature.

     

    Derivative financial instruments: The Company accounts for derivative instruments in accordance with ASC 815, Derivatives and Hedging (“ASC 815”). The Company’s objectives and strategies for using derivative instruments, and how the derivative instruments and related hedged items are accounted for affect the consolidated financial statements. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risk.

     

    The Company evaluates all of its financial instruments, including notes payable and warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company applies significant judgment to identify and evaluate complex terms and conditions in its contracts and agreements to determine whether embedded derivatives exist. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract on the Company’s balance sheet.

     

    An evaluation of specifically identified conditions is made to determine whether the fair value of the derivative issued is required to be classified as equity or as a derivative liability. Changes in the estimated fair value of the liability-classified derivative financial instruments are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations and comprehensive loss.

     

    Stock purchase warrants: The Company accounts for stock purchase warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing liabilities from equity (“ASC 480”), and ASC 815. The assessment considers whether the stock purchase warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the stock purchase warrants meet all of the requirements for equity classification under ASC 815, including whether the stock purchase warrants are indexed to the Company’s own common shares and whether the holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance, modification, and as of each subsequent quarterly period end date while the stock purchase warrants are outstanding.

     

    For issued or modified stock purchase warrants that meet all of the criteria for equity classification, the stock purchase warrants are required to be recorded as a component of additional paid-in capital at the time of issuance.

     

    For issued or modified stock purchase warrants that do not meet all the criteria for equity classification, the stock purchase warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability classified stock purchase warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations and comprehensive loss.

     

    The Company assesses the classification of its common stock purchase warrants at each reporting date to determine whether a change in classification between equity and liability is required. For modified stock purchase warrants that result in a change of classification from equity to liability, a liability is recognized equal to the fair value on the date of modification, additional paid-in capital is adjusted by the fair value of the warrant on the date of issuance, and the difference is recognized as a non-cash gain or loss on the accompanying consolidated statements of operations and comprehensive loss.

     

    11

     

     

    Assets held for sale: Assets held for sale represent property, equipment, and leasehold improvements less accumulated depreciation as well as any other assets that are held for sale in conjunction with the sale of a business. The Company records assets held for sale in accordance with ASC 360 at the lower of carrying value or fair value less costs to sell. Fair value is the amount obtainable from the sale of the asset in an arm’s length transaction. The reclassification takes place when the assets are available for immediate sale and the sale is highly probable. These conditions are usually met from the date on which a letter of intent or agreement to sell is ready for signing.

     

    Discontinued operations: A component of an entity is identified as operations and cash flows that can be clearly distinguished, operationally and financially, from the rest of the entity. Under ASC 205-20, “Presentation of Financial Statements - Discontinued Operations” (“ASC 205-20”), a discontinued operation is a component of an entity that either has been disposed of, or is classified as held for sale and represents a strategic shift that has or will have a major effect on the entity’s operations and financial results, or a newly acquired business or nonprofit activity that upon acquisition is classified as held for sale. Discontinued operations are presented separately from continuing operations in the consolidated statements of Operations and the consolidated statements of cash flows (see Note 4). For long-lived assets or disposals groups that are classified as held for sale but do not meet the criteria for discontinued operations, the assets and liabilities are presented separately on the balance sheet of the initial period in which it is classified as held for sale.

     

    Advertising: Costs related to advertising are expensed as incurred. For the three months ended March 31, 2025 and 2024, the Company had no advertising costs.

     

    Stock-based compensation: The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based awards, including stock options and stock grants, based on estimated grant-date fair values. The Company measures employee, director and nonemployee awards at the date of grant, which generally is the date at which the Company and the nonemployee reach a mutual understanding of the key terms and conditions of a share-based payment award.

     

    The Company estimates the grant date fair value of each stock option award using the Black-Scholes option-pricing model. The model requires management to make a number of assumptions, including the fair value and expected volatility of the Company’s underlying common stock price on the date of grant, expected live of the option, risk-free interest rate and expected dividend yield. The Company sets the grant date fair value of each stock grant equal to the fair value of the Company’s common stock on the date of grant.

     

    The Company uses the straight-line attribution method to allocate compensation cost to reporting periods over the requisite service period during which the employee, board member, director, or advisor is required to provide services in exchange for the award. The Company has elected to account for forfeitures of awards as they occur, with previously recognized compensation reversed in the period that the awards are forfeited.

     

    Income taxes: The Company accounts for income taxes using the asset and liability method whereby deferred tax assets and liabilities are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when management estimates that it is more likely than not that deferred tax assets will not be realized. Realization of deferred tax assets is dependent upon future pre-tax earnings, the reversal of temporary differences between book and tax income, and the expected rates in future periods.

     

    The Company is required to evaluate the tax positions taken in the course of preparing its tax returns to determine whether tax positions are more likely than not of being sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the “more-likely-than-not” threshold would be recorded as a tax expense in the current year. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount that is initially recognized. The Company recognizes interest and penalties related to income tax matters in general and administrative expense.

     

    For U.S. federal tax purposes, digital asset transactions are treated on the same tax principles as property transactions. The Company recognizes a gain or loss when digital assets are exchanged for other property, in the amount of the difference between the fair market value of the property received and the tax basis of the exchanged digital assets. Receipts of digital assets in exchange for goods or services are included in taxable income at the fair market value on the date of receipt.

     

    12

     

     

    Foreign currency translation: The Company’s consolidated financial statements are presented in the reporting currency of the U.S. dollar. Functional currencies of the Company and its wholly-owned subsidiaries is the local currency used in each entities primary economic environment, some of which are different than the reporting currency. Assets and liabilities of the Company are translated into the reporting currency using the exchange rate in effect at the balance sheet dates. Equity transactions are translated using the historical exchange rate in effect on the date of the transaction, except for the change in accumulated deficit during the year, which is the results of the operations translation process. Results of operations and cash flows are translated using the weighted average exchange rates in effect during the period. As a result, amounts relating to the assets and liabilities reported on the statements of cash flows may not necessarily agree with the changes in the corresponding balances on the accompanying consolidated balance sheets. Translation adjustments resulting from the process of translating the local currency financial statements into the reporting currency are recorded as a component of comprehensive income (loss). The realized foreign currency exchange gain (loss) and the unrealized foreign currency exchange gain (loss) for the three months ended March 31, 2025 and 2024 is included as a component of net loss from discontinued operations on the accompanying consolidated statements of operations and comprehensive loss.

     

    Remeasurement gains and losses from transactions that are not denominated in the functional currency are recorded as a component of other income in the consolidated statements of operations and comprehensive loss. Most of the Company’s revenue transactions are transacted in the functional currency of the Company. The Company does not enter into any material transaction in foreign currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of the Company.

     

    Comprehensive loss: Comprehensive loss is comprised of net loss and all changes to the statements of equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. For the Company, comprehensive loss for the three months ended March 31, 2025 and 2024 consisted of net loss and unrealized loss from foreign currency translation adjustment.

     

    Net loss per share: Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period, excluding the effects of any potential dilutive securities. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common share equivalents had been issued and if the additional common shares were dilutive. Earnings per share excludes all potential dilutive shares of common shares if their effect is anti-dilutive

     

    For the three months ended March 31, 2025 and 2024, potentially dilutive common shares consist of the common shares issuable upon the exercise of common stock options and warrants (using the treasury stock method) and the conversion of convertible notes payable. In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact.

     

    The following table summarizes the potentially dilutive securities excluded from the computation of diluted shares outstanding because the effect of including these potential shares was anti-dilutive:

     

       Three Months Ended
    March 31,
     
       2025   2024 
    Options to purchase common stock   4,823    15,538 
    Convertible notes payable that convert into common stock   
    —
        
    —
     
    Stock purchase warrants to acquire common stock   5,192,381    837,625 
    Total potentially dilutive securities   5,197,204    853,163 

     

    Recently issued accounting pronouncements, adopted

     

    ASU 2023-07, Segment Reporting – Improvements to Reportable Segment Disclosures (“ASU 2023-07”), requires enhanced disclosures related to significant segment expenses and a description of how the chief operating decision maker utilizes segment operating profit or loss to assess segment performance. ASC 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim reporting periods starting after December 15, 2024, and is to be applied retrospectively. The Company adopted ASU 2023-07 for the three months ended March 31, 2025 and its adoption did not have a material impact on the consolidated financial statements.

     

    13

     

     

    Recently issued accounting pronouncements, not yet adopted

     

    ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”) incorporates several disclosure and presentation requirements currently residing in SEC Regulation S-X and S-K into the ASC. The amendments are applied prospectively and are effective when the SEC removes the related requirements from Regulation S-X and S-K. Any amendments the SEC does not remove by June 30, 2027 will not be effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its disclosures.  

     

    ASU 2023-09, Income Taxes (“ASU 2023-09”), requires disclosure of specific categories and disaggregation of information in the rate reconciliation table and expands disclosures related to income taxes paid. The new standard is effective for fiscal years beginning after December 15, 2024 and is to be applied prospectively. The Company is currently evaluating the impact, if any, adoption will have on its consolidated financial statements and disclosures.

     

    ASU 2024-02, Codification Improvements-Amendments to Remove References to the Concepts Statements (“ASU 2024-02”) updates accounting standards for revenue recognition (ASC 606), lease accounting (ASC 842), and impairment of long-lived assets (ASC 360). ASU 2024-02 provides enhanced guidance for estimating variable consideration, accounting for contract modifications, determining lease terms, and simplifying impairment testing for long-lived assets. It also introduces increased disclosure requirements for financial instruments and derivatives. ASU 2024-02 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact, if any, adoption will have on its consolidated financial statements and disclosures.

     

    ASU 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”), requires public companies to disaggregate key expense categories, such as inventory purchases, employee compensation and depreciation in their financial statements. This aims to improve investor insight into company performance. ASU 2024-03 is effective for fiscal years beginning after December 15, 2024, and interim periods within fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact, if any, adoption will have on its consolidated financial statements and disclosures.

     

    NOTE 4 – DISCONTINUED OPERATIONS

     

    In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major impact on an entity’s operations and financial results when the components of an entity meets the criteria in ASC paragraph 205-20-45-10. In the period in which the component meets the held for sale or discontinued operations criteria the major assets, other assets, current liabilities and non-current liabilities shall be reported as a component of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the income (loss) of continuing operations.

     

    Disposition of a Subsidiary: On November 8, 2024, the Company entered into a Settlement Agreement and Release (the “Settlement Agreement”) with a shareholder of the Company and a subsidiary of the Company to sell the subsidiary to the shareholder or his nominee subject to the Company obtaining shareholder approval. As required by the Settlement Agreement, a Share Purchase Agreement was entered into between the same parties dated December 23, 2024 providing that the Company, subject to it obtaining shareholder approval, will sell the subsidiary to the officer of the Company in consideration of GBP 1,000 (approximately $1,294 at March 31, 2025).

     

    The subsidiary comprises our financial services operating segment. As a result of the planned disposition of the subsidiary, the financial services operating segment meets the held for sale criteria of ASC 205-20. Accordingly, the historical results of operations of the financial services operating segment has been reflected as discontinued operations in our consolidated financial statement for all periods prior to the Settlement Agreement on November 8, 2024.

     

    General Support Services Reporting Segment: In connection with a securities and purchase agreement and call option the Company entered into on December 15, 2024 to acquire a business (see Note 12) and the disposition of a subsidiary, the Company’s business will be focused on the defense sector. As of December 15, 2024, the Company determined that it would cease operations of its General Support Services operating segment. As a result, the general support services operating segment meets the discontinued operations criteria of ASC 205-20. Accordingly, the historical results of operations of the financial services operating segment has been reflected as discontinued operations in our consolidated financial statement for all periods prior to December 15, 2024.

     

    14

     

     

    Summary Reconciliation of Discontinued Operations

     

    The following tables present the balance sheets and the results of operations of the Company classified as discontinued operations for the periods presented:

     

    NUKKLEUS INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

     

       March 31,   December 31, 
       2025   2024 
       (Unaudited)   (Audited) 
    ASSETS        
    CURRENT ASSETS:        
    Cash and cash equivalents  $14,533   $148,679 
    Customer custodial funds   1,260,839    811,265 
    Customer digital currency assets   813,165    22,930 
    Digital assets   407    550 
    Due from affiliates   
    -
        50,768 
    Other current assets   38,176    54,860 
               
    TOTAL CURRENT ASSETS   2,127,120    1,089,052 
               
    NON-CURRENT ASSETS:          
    Intangible assets, net   11,646    14,887 
               
    TOTAL NON-CURRENT ASSETS   11,646    14,887 
    TOTAL ASSETS  $2,138,766   $1,103,939 
               
    LIABILITIES AND STOCKHOLDERS’ DEFICIT          
               
    CURRENT LIABILITIES:          
    Accounts payable  $526,045   $504,249 
    Customer custodial cash liabilities   2,221,182    972,941 
    Customer digital currency liabilities   9,057    10,514 
    Due to affiliates   515,406    479,608 
    Loans payable - related parties, current   704,043    682,875 
    Interest payable - related parties, current   245,008    203,755 
    Accrued expenses and other current liabilities   214,495    308,567 
               
    TOTAL CURRENT LIABILITIES   4,435,236    3,162,509 
               
    NON-CURRENT LIABILITIES:          
    Loan payable - related parties, net of current portion   17,906    17,368 
               
    TOTAL NON-CURRENT LIABILITIES   17,906    17,368 
               
    TOTAL LIABILITIES   4,453,142    3,179,877 

     

    The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

     

    15

     

     

    NUKKLEUS INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

     

       For the Three Months Ended
    March 31,
     
       2025   2024 
    REVENUES        
    Revenue - financial services  $187,469    259,757 
    Total revenues   187,469    259,757 
               
    COSTS OF REVENUES          
    Cost of revenue - financial services   22,132    63,196 
    Total costs of revenues   22,132    63,196 
               
    GROSS PROFIT (LOSS)          
    Gross profit (loss) - financial services   165,337    196,561 
    Total gross profit (loss)   165,337    196,561 
               
    OPERATING EXPENSES:          
    Advertising   
    -
        20,568 
    Professional fees   105,227    206,660 
    Compensation and related benefits   134,640    239,848 
    Amortization of intangible assets   3,275    3,466 
    Other general and administrative   74,210    60,693 
               
    Total operating expenses   317,352    531,235 
               
    LOSS FROM OPERATIONS   (152,015)   (334,674)
               
    OTHER (EXPENSE) INCOME:          
    Interest expense - related parties   (80,703)   (308)
    Other income (expense)   49,963    766 
               
    Total other income (expense), net   (30,740)   458 
               
    LOSS BEFORE INCOME TAXES   (182,755)   (334,216)
               
    INCOME TAXES   
    -
        
    -
     
               
    NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS  $(182,755)  $(334,216)

     

    The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

     

    16

     

     

    NOTE 5 – LOANS PAYABLE – RELATED PARTIES

     

    The Company’s loans payable – related parties consisted of the following:

     

    During the twelve months ended September 30, 2024, the Company issued promissory notes in the aggregate principal of $1,105,639 and $248,000 to a shareholder and to an entity managed by that shareholder, respectively, (collectively, the “Shareholder 2024 Loans”), in consideration of cash proceeds in the same amount in the following tranches:

     

    October 2023  $199,000 
    December 2023   424,000 
    January 2024   25,000 
    February 2024   188,000 
    March 2024   80,000 
    April 2024   31,000 
    May 2024   100,000 
    June 2024   120,500 
    July 2024   59,000 
    August 2024   58,000 
    September 2024   69,139 
    Total  $1,353,639 

     

    The 2024 Shareholder Loans bear interest of 5.0% per annum and each individual loan will be due and payable three years from the date of issuance. As of December 31, 2024, the outstanding principal balance and accrued and unpaid interest of the Shareholder 2024 Loans was $1,353,639 and $44,111, respectively.

     

    In July 2024, a shareholder of the Company made payments on the Company’s behalf to settle an obligation with an affiliate in which the shareholder has a controlling interest. The shareholder entered into an assignment of debt agreement with the affiliate whereby the affiliate assigned its right, title obligation and interest in the obligation by the Company to the shareholder (the “July 2024 Loan”). The July 2024 Loan is noninterest bearing and was due and payable at issuance. In December 2024, the Company repaid approximately $1,000,000 of the July 2024 loan. As of March 31, 2025, the outstanding principal balance of the July 2024 Loan was $213,349.

     

    As of March 31, 2025 and December 31, 2024, total loans payable – related parties was $1,566,988 and $1,566,988, respectively, which was reflected as loans payable – related parties, current and noncurrent, on the accompanying consolidated balance sheets.

     

    In June 2024, as part of the terms of a note payable entered into, 30.0% of the loans payable with the shareholder of the 2024 Shareholder Loans and July 2024 Loan was due and payable on demand.

     

    For the three months ended March 31, 2025 and 2024, the interest expense related to above loans payable – related parties amounted to $33,841 and $10,025, respectively, and has been reflected as a component of other (expense) income on the accompanying consolidated statements of operations and comprehensive loss.

     

    As of March 31, 2025 and December 31, 2024, the related accrued and unpaid interest for above loans was $77,952 and $44,111, respectively, which was reflected as interest payable – related parties, net of current portion on the accompanying consolidated balance sheets.

     

    The loans payable – related parties mature as follows:

     

    For the Period Ending:    
    March 31, 2025  $619,440 
    December 31, 2026   947,548 
       $1,566,988 

     

    17

     

     

    NOTE 6 – NOTE PAYABLE, NET

     

    In April 2024, the Company issued a promissory note in the principal amount of $78,000 to an investor   in consideration of cash proceeds in the same amount (the “April 2024 Loan”). In addition, the Company issued a stock purchase warrant for the purchase of 14,535 shares of the Company’s common stock (the “April 2024 Warrant”) that is exercisable for three years at an exercise price of $0.86 per warrant. The April 2024 Loan bears interest of 8.0% per annum and is due and payable on April 30, 2025. The April 2024 Warrant was determined to be an equity classified warrant and fair value of $40,804   determined using the Black-Scholes option-pricing model with the following assumptions: volatility of 174.03%, risk-free rate of 4.87%, annual dividend yield of 0.0% and expected life of 3 years. The principal amount of the April 2024 Loan was allocated to the April 2024 Loan and April 2024 Warrant in the amount of $37,196 and $40,804, respectively. The amount allocated to the April 2024 Warrant were recorded as a discount on the April 2024 Loan.

     

    Amortization of the debt discount and interest expense related to the April 2024 Loan amounted to $10,201 and $1,539, respectively, for the three months ended March 31, 2025 and $0 and $0, respectively, for the three months ended March 31, 2024, which are both included as a component of interest expense on the accompanying consolidated statements of operations and comprehensive loss.

     

    The balance of the April 2024 Loan, net of unamortized discount, was $74,600 and $64,399 as of March 31, 2025 and December 31, 2024, respectively and reflected as note payable, net on the accompanying consolidated balance sheets.

     

    NOTE 7 – CONVERTIBLE NOTES PAYABLE, NET

     

    The Company’s convertible notes payable consisted of the following:

     

       March 31,   December 31, 
       2025   2024 
    August 2024 Note  $515,000   $515,000 
    December 2024 Note   500,000    500,000 
        1,015,000    1,015,000 
    Less: debt issuance costs   (183,377)   (308,646)
    Convertible notes payable, net  $831,623   $706,354 

     

    August 2024 Note: In August 2024, the Company issued a senior unsecured promissory note (the “August 2024 Note”) in the principal amount of $515,000 to a new lender in consideration of cash proceeds in the amount of $412,075. The August 2024 Note bears interest of 12.0% per annum and is due and payable six months after issuance. The lender shall have the right to convert the principal and interest payable under the August 2024 Note into shares of common stock of the Company at a per share conversion price of $2.50. In addition, the Company issued the lender a stock purchase warrant (the “August 2024 Warrant”) to acquire 175,000 shares of common stock at a per share price of $2.00 for a term of five years that may be exercised on a cash or cashless basis. The number of shares and exercise prices for the August 2024 Note and August 2024 Warrant reflect the October 2024 reverse stock split.

     

    The August 2024 Warrant was determined to be an equity classified warrant and fair value was calculated as $447,316 using the Black-Scholes option-pricing model with the following assumptions: volatility of 183.31%, risk-free rate of 3.84%, annual dividend yield of 0.0% and expected life of five years. The Company recorded a total debt discount of $342,314 related to the original issue discount and August 2024 Warrant, which will be amortized over the term of the August 2024 Note. The principal amount of the August 2024 Note was allocated to the August 2024 Note and the August 2024 Warrant in the amount of $275,611 and $239,389, respectively. The amount allocated to the original issue discount and the August 2024 Warrant were recorded as a discount on the August 2024 Note, which will be amortized to interest expense using the effective interest rate method over the term of the August 2024 Note.

     

    The Company did not obtain the Lender’s written consent prior to entering into the August 2024 Note, violating the terms of the Restructuring Agreement. Accordingly, the Lender exercised its right to terminate the current CEO and appoint an additional member to the Board. 

     

    18

     

     

    December 2024 Note: On December 3, 2024, the Company issued a convertible promissory note (the “December 2024 Note”) in the principal amount of $500,000 to a lender, in consideration of cash proceeds in the amount of $450,000 after an original issue discount of $25,000 and issuance costs of $25,000 in connection with the standby equity purchase agreement executed with the lender (the “SEPA”). The December 2024 Note matures on December 3, 2025. The SEPA was subsequently terminated in December 2024. The December 2024 Note has the following features:

     

    Conversion rights – The December 2024 Note and accrued and unpaid interest is convertible at the option of the lender (the “Conversion Option”) into shares of the Company’s common stock at a per share conversion price of the lower of (i) $2.00 per share (the “Fixed Price”) and (ii) 90% of the lowest daily volume weighted average price (the “VWAP”) during the ten consecutive trailing days immediately preceding the conversion, with a floor of $0.33 (the “Floor Price”).

     

    Interest – The December 2024 Note bears interest of 10.0% per annum. Upon an event of default, the December 2024 Note becomes immediately due and payable, with the interest increasing to 18.0%.

     

    Optional redemption – The December 2024 Note is redeemable by the Company in the event that the VWAP of the Company’s common stock was less than the Fixed Price on the date the Company provides the redemption notice to the lender. The redemption price will be equal to the outstanding principal amount of the December 2024 Note plus the 10% of the principal amount being redeemed (the “Redemption Premium”) plus all accrued and unpaid interest, if any. The lender has ten days from the date the redemption notice is received to elect to convert all or a portion of the December 2024 Note.

     

    Event of Default – If any event of default as defined in the December 2024 Note occurs, the full unpaid principal amount of the December 2024 Note, accrued and unpaid interest, and other amounts owed become at the lender’s election immediately due and payable in cash. The lender has the right, but not the obligation, to convert all or part of the December 2024 Note in accordance with the terms of the December 2024 Note.

     

    Exchange Cap – The lender shall not have the right to convert any portion of the December 2024 Note to the extent that after giving effect to such conversion, the lender, along with its affiliates, would beneficially own in excess of 4.99% of the outstanding common stock immediately after giving effect to such conversion (the “Exchange Cap”), unless the Company has obtained shareholder approval for conversion.

     

    Amortization Event – In no event shall the lender be allowed to effect a conversion if such conversion, along with all other shares of common stock then beneficially owned by the lender and its affiliates would exceed 4.99% of the then outstanding shares of the common stock of the Company. If at any time (i) the daily VWAP is less than the Floor Price for three trading days during a period of five consecutive trading days (a “Floor Price Event”), (ii) the Company has issued in excess of 99.0% of the shares of common stock available under the Exchange Cap (an “Exchange Cap Event”), or (iii) at any time after the effectiveness deadline set forth in the Registration Rights Agreement, dated as of December 3, 2024, by and between the Company and the lender (the “Registration Rights Agreement”), the lender is unable to utilize a registration statement to resell the shares of the Company’s common stock receivable by the lender for a period of ten consecutive trading days (a “Registration Event,” and collectively with a Floor Price Event and an Exchange Cap Event, each an “Amortization Event”), then the Company shall make monthly payments to the lender beginning on the seventh trading day after the Amortization Event and continuing monthly in the amount of $150,000 plus a 10.0% premium and accrued and unpaid interest. The Exchange Cap Event will not apply in the event the Company has obtained the approval from its stockholders for the issuance of shares of common stock pursuant to the conversion of the December 2024 Note in excess of the Exchange Cap.

     

    Embedded Derivatives – The optional redemption and event of default include an exercise contingency, which requires the Company to obtain shareholder approved for conversions subject to the Exchange Cap, which fails the equity classification guidance in ASC 815 and is thus precluded from being classified in equity. Therefore, the embedded derivatives are required to be bifurcated from the December 2024 Note and accounted for at fair value at each reporting date. A fair value of $222,865 was determined for the embedded derivative liabilities using a Monte Carlo Simulation model. The embedded derivative liabilities will be re-measured to fair value each reporting period until settlement (see Note 10).

     

    For the three months ended March 31, 2025, amortization of debt discount and interest expense related to convertible promissory notes amounted to $125,269 and $27,567, respectively, which are both included as a component of interest expense on the accompanying condensed consolidated statements of operations and comprehensive loss.

     

    19

     

     

    NOTE 8 – STOCKHOLDERS’ DEFICIT

     

    As a result of the 2024 Reverse Stock Split, each eight pre-split shares of common stock outstanding automatically combined and converted to one issued and outstanding share of common stock without any action on the part of stockholders. No fractional shares of common stock were issued to any stockholders in connection with the 2024 Reverse Stock Split. Each stockholder was entitled to receive one share of common stock in lieu of the fractional share that would have resulted from the 2024 Reverse Stock Split. The number of the Company’s authorized common stock remain unchanged, and the par value of the common stock following the 2024 Reverse Stock Split remained at $0.0001 per share.

     

    Preferred Stock: The Company is authorized to issue 15,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, option or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. As of March 31, 2025 and December 31, 2024, there were no shares of preferred stock issued and outstanding.

     

    Common stock: The Company is authorized to issue 150,000,000 shares of common stock with a par value of $0.0001 per shares, of which 5,013,863 and 4,930,531 shares were issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. The following shares of common stock are reserved for future issuance:

     

    Convertible notes payable   480,608 
    Stock options issued and outstanding   104,823 
    Stock purchase warrants   5,381,916 
        5,967,347 

     

    Dividend rights: the holders of common stock are entitled to receive dividends and other distributions, as and if declared by the Board out of assets or funds of the Company legally available and shall share equally on a per share basis.

     

    Voting rights: the common stock possesses all voting power of the Company. Each share of common stock is entitled to one vote.

     

    Liquidation: In the event of any liquidation, dissolution or winding up of the Company, after payment or provision of payment of the debts and other liabilities of the Company, the holders of common stock are entitled to receive the remaining assets of the Company available for distribution ratably in proportion to the number of shares of common stock held by them.

     

    Common Stock Issuances:

     

    On December 18, 2024, the Company entered into a securities purchase agreement for a private placement (the “Private Placement”) pursuant to which an investor purchased from the Company 1,666,666 units for an aggregate purchase price of $9,999,996 or a per unit price of $6.00 with each unit consisting of (i) one share of the Company’s common stock and (ii) a stock purchase warrant to purchase up to one and one half shares of the Company’s common stock (the “Private Placement Warrant”). The investor may elect to acquire one pre-funded common stock purchase warrant in lieu of one share (the “Pre-Funded Warrant”). The Units were priced in excess of the average Nasdaq Official Closing Price of the Company’s common stock for the five trading days immediately preceding the signing of the Private Placement. The Private Placement closed on December 20, 2024. Issuance costs totaled $865,143 and were recorded as a reduction to additional paid-in capital. On December 19, 2024, 230,000 shares of common stock were issued in connection with the Private Placement.

     

    The Pre-funded Warrant and the Private Placement Warrant permit the investor to acquire a fixed amount of shares of the Company’s common stock at a per share price of $0.0001 and $6.00, respectively, that may be exercised on a cash or cashless basis. The Pre-Funded Warrant is immediately exercisable, at a nominal exercise price of $0.0001 per share, and may be exercised at any time until the Pre-Funded Warrant is fully exercised. The Private Placement Warrant has an exercise price of $6.00 per share, is immediately exercisable on a cash or cashless basis and will expire five years from the date of issuance. The Pre-funded Warrant and the Private Placement Warrant were determined to be liability-classified at the time of issuance.

     

    20

     

     

    In February 2025, the investor sold 83,333 and 125,000 units in relation to the Pre-funded Warrant and Private Placement Warrant, respectively, to a third party. In February 2025, the third party submitted a cashless exercise of their 83,333 units in relation to the Pre-funded warrant, which resulted in an issuance of 83,332 shares of common stock. This issuance was the sole issuance of common stock during the three months ending March 31, 2025.

     

    During the three months ending March 31, 2024, the Company issued 25,338 shares of common stock to settle an obligation to a vendor.

     

    Warrants:

     

    Public Warrants: On June 26, 2020, Brilliant completed an initial public offering that included warrants for shares of common stock (the “Public Warrants’). Each Public Warrant entitles the holder the right to purchase one share of common stock at an exercise price of $11.50 per share. No fractional shares will be issued upon exercise of the Public Warrants. The Company may elect to redeem the Public Warrants, in whole and not in part, at a price of $0.01 per Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company’s common stock equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders have a period of 30 days to exercise for cash, or on a cashless basis. On the Closing Date, there were 805,000 Public Warrants issued and outstanding.

     

    Private Warrants: Simultaneous with Brilliant’s initial public offering in June 2020, Brilliant sold warrants to its sponsor and certain of its directors and advisors in a private placement (the “Private Warrants”). The Private Warrants may not be redeemed by the Company so long as the Private Warrants are held by the initial purchasers, or such purchasers’ permitted transferees. The Private Warrants have terms and provisions identical to the Public Warrants, including as to exercise price, exercisability and exercise period, except if the Private Warrants are held by someone other than the initial purchasers’ permitted transferees, then the Private Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. On the Closing Date, there were 32,625 Private Warrants issued and outstanding.

     

    As a result of the Business Combination which was completed on December 22, 2023, Public Warrants and Private Warrants totaling 837,625 were converted into 837,625 warrants of the Company.

     

    Stock Purchase Warrants: In connection with certain note payable agreements (see Note 6) certain convertible notes payable (see Note 7), and the Private Placement (see Note 8) the Company issued stock purchase warrants to certain lenders and investors that permit the lender or investor to acquire a fixed amount of shares of the Company’s common stock at a per share price that ranges between $.0001 and $6.88 for a term that ranges between three and five years that may be exercised on a cash or cashless basis.

     

    Certain warrants were determined to be equity-classified at issuance, and as such, were recorded to additional-paid-in capital at the time of issuance. Certain warrants were determined to be liability-classified at issuance, and as such, were recorded at fair value as a liability on the accompanying consolidated balance sheets and re-measured to fair value each reporting period with the change in fair value recorded as a component of other income (expense) on the accompanying consolidated statements of operations and comprehensive loss. Certain warrants were modified during the three months ended December 31, 2024 at which time the warrant’s classification was re-assessed and the classification changed from equity to liability.

     

    21

     

     

    The following table summarizes the shares of the Company’s common stock issuable upon exercise of warrants outstanding at March 31, 2025:

     

       Warrants Outstanding 
       Range of
    Exercise
    Price
       Number
    Outstanding at
    March 31,
    2025
       Weighted
    Average
    Remaining
    Contractual
    Life (Years)
       Weighted
    Average
    Exercise
    Price
     
    Public and Private Warrants  $92.00    837,625    0.58   $14.32 
    April 2024 Warrants   6.88    14,535    0.01    0.02 
    June 2024 Warrants   2.00    150,000    0.12    0.06 
    August 2024 Warrants   2.00    175,000    0.14    0.07 
    November 2024 Warrant   2.41    351,424    0.30    0.16 
    Pre-funded Warrants   0.0001    1,353,333    1.18    0.00 
    Private Placement Warrant   6.00    2,499,999    2.19    2.79 
       $0.0001 – 92.00    5,381,916    4.52   $17.42 

     

    The following table summarizes the shares of the Company’s common stock issuable upon exercise of warrants outstanding at December 31, 2024:

     

       Warrants Outstanding 
       Range of
    Exercise
    Price
       Number
    Outstanding at
    December 31,
    2024
       Weighted
    Average
    Remaining
    Contractual
    Life (Years)
       Weighted
    Average
    Exercise
    Price
     
    Public and Private Warrants  $92.00    837,625    0.61   $14.10 
    April 2024 Warrants   6.88    14,535    0.01    0.02 
    June 2024 Warrants   2.00    150,000    0.12    0.05 
    August 2024 Warrants   2.00    175,000    0.15    0.06 
    November 2024 Warrant   2.41    351,424    0.31    0.15 
    Pre-funded Warrants   0.0001    1,436,666    1.30    0.00 
    Private Placement Warrant   6.00    2,499,999    2.27    2.74 
       $0.0001 – 92.00    5,465,249    4.77   $17.12 

     

    Warrant activities for the three months ended March 31, 2025 were as follows:

     

       Number of
    Options
       Weighted
    Average
    Exercise
    Price
     
    Outstanding at December 31, 2024   5,465,249    17.12 
    Exercised   (83,333)   
    -
     
    Outstanding at March 31, 2025   5,381,916   $17.42 

     

    22

     

     

    NOTE 9 – STOCK-BASED COMPENSATION

     

    Old Nukk Equity Incentive Plan

     

    For periods prior to the reverse recapitalization, the Old Nukk Equity Incentive Plan (the “Old Nukk Plan”) permitted the granting of various awards including stock options (including both nonqualified options and incentive options), stock appreciate rights (“SARs”), stock awards, phantom stock units, performance awards and other share-based awards to employees, outside directors and consultants, and advisors to the Company. Only stock options have been awarded to consultants and advisors under the Old Nukk Plan.

     

    Assumed Options converted into an option to purchase a number of shares of the Company’s common stock equal to the product of the number of shares of Old Nukk common stock and the Exchange Ratio at an exercise price per share equal to the exercise price of the Assumed Options divided by the Exchange Ratio. Each Assumed Option is governed by the same terms and conditions applicable to the Assumed Options prior to the Business Combination. No further grants can be made under the Old Nukk Plan.

     

    2024 Equity Incentive Plan

     

    On October 11, 2024, the Company’s shareholders approved a new long-term incentive award plan (the “2024 Plan”). The 2024 Plan is administered by the Board. The selection of participants, allotment of shares, determination of price and other conditions are approved by the Board at its sole discretion to attract and retain personnel instrumental to the success of the Company.

     

    On November 13, 2024, the Company issued 100,000 stock options to a consultant of the Company.

     

    Stock options generally vest over one to three years, with a maximum term of ten years from the date of grant. These awards become available to the recipient upon the satisfaction a vesting condition based on a period of service. Total stock options activity for the three months ended March 31, 2025 is summarized as follows:

     

       Number of
    Options
       Weighted
    Average
    Exercise
    Price
     
    Outstanding at December 31, 2024   104,823   $27.61 
    Expired   
    -
        
    -
     
    Outstanding at March 31, 2025   104,823    27.61 
    Options exercisable at March 31, 2025   104,823   $27.61 
    Options expected to vest   
    —
       $
    —
     

     

    Share-based compensation expense for three months ended March 31, 2025 and 2024 was $177,905 and $74,668, respectively, which was recorded as professional fees on the accompanying consolidated statements of operations and comprehensive loss. There was no unrecognized share-based compensation at March 31, 2025.

     

    23

     

     

    NOTE 10 – FAIR VALUE MEASUREMENT

     

    Customer digital currency assets and liabilities represent the Company’s obligation to safeguard customer digital currencies. Accordingly, the Company has valued the assets and liabilities using quoted market prices for the underlying digital currencies which is based on Level 2 inputs.

     

    The Black-Scholes option pricing model is used to estimate fair value of liability-classified stock purchase warrants issued in connection with convertible notes (see Note 7) and the liability-classified pre-funded stock purchase warrants issued in connection with the December 2024 Private Placement (see Note 8). A Monte Carlo simulation model is used to estimate the fair value of liability-classified stock purchase warrants issued in connection with the December 2024 Private Placement (see Note 8). Both models utilize the following assumptions:

     

      ● Risk-free interest rates are derived from the yield on U.S. Treasury debt securities in effect on the date of measurement.

     

      ● Dividend yields are based on our historical dividend payments, which have been zero to date.

     

      ● Volatility is estimated from historical volatility of a peer group over a similar period.

     

      ● The expected term is based on the time to expiration of the warrants from the date of measurement.

     

    The Monte Carlo simulation model also incorporates management’s judgments for the occurrence or non-occurrence of certain events as well as the probability of certain scenarios impactful to the valuation of the liability-classified stock purchase warrants issued in connection with the December 2024 Private Placement.

     

    The assumptions used for the Black-Scholes option pricing model for liability-classified stock purchase warrants are as follows:

     

    June 2024 Warrants  March 31,
    2025
       November 2024
    Modification
     
    Expected term (years)   4.2 years    4.6 years 
    Risk-free interest rate   3.9%   4.4%
    Expected volatility   113.8%   113.8%
    Expected dividend yield   0.0%   0.0%

     

    November 2024 Warrants  March 31,
    2025
       November 2024
    Issuance
     
    Expected term (years)   4.6 years    5.0 years 
    Risk-free interest rate   3.9%   4.2%
    Expected volatility   113.8%   113.8%
    Expected dividend yield   0.0%   0.0%

     

    Pre-funded Warrants  March 31,
    2025
       December 2024
    Issuance
     
    Expected term (years)   4.7 years    5.0 years 
    Risk-free interest rate   3.9%   4.3%
    Expected volatility   113.8%   113.8%
    Expected dividend yield   0.0%   0.0%

     

    24

     

     

    The assumptions used for the Monte Carlo simulation model for liability-classified stock purchase warrants and the embedded derivative liability issued in connection with a convertible note are as follows:

     

    December 2024 Warrants  March 31,
    2025
       December 2024
    Issuance
     
    Expected term (years)   4.7 years    5.0 years 
    Risk-free interest rate   3.9%   4.3%
    Expected volatility   113.8%   113.8%
    Expected dividend yield   0.0%   0.0%
    Probability of a fundamental event   10.0%   10.0%

     

    Embedded Derivative Liability  March 31,
    2025
       December 2024
    Issuance
     
    Expected term (years)   0.7 years    1.0 years 
    Risk-free interest rate   4.2%   4.3%
    Expected volatility   160.8%   157.5%
    Expected dividend yield   0.0%   0.0%
    Conversion discount   10.0%   10.0%
    Interest rate   10.0%   10.0%
    Redemption premium  $50,000   $50,000 

     

    The following table sets forth by level, within the fair value hierarchy, the Company’s assets and liabilities measured and recorded at fair value on a recurring basis as of March 31, 2025:

     

       Quoted
    Price in
    Active Markets
       Significant
    Other
    Observable
    Inputs
       Significant
    Unobservable
    Inputs
       Balance at
    March 31,
     
       (Level 1)   (Level 2)   (Level 3)   2025 
    Liabilities                
    June 2024 Warrant   
          —
        
           —
        1,648,465    1,648,465 
    November 2024 Warrant   
    —
        
    —
        3,850,947    3,850,947 
    Pre-funded warrant liabilities   
    —
        
    —
        16,091,019    16,091,019 
    Private Placement Warrants   
    —
        
    —
        35,845,993    35,845,993 
    Embedded derivative liability   
    —
        
    —
        280,340    280,340 
    Total liabilities  $
    —
       $
    —
       $57,716,764   $57,716,764 

     

    The Company did not make any transfers into or out of Level 3 of the fair value hierarchy during the three months ended March 31, 2025.

     

    The following table provides a reconciliation of the warrants measured at fair value using Level 3 inputs:

     

       Embedded
    Derivative
    Liability
       June 2024
    Warrant
       November 2024
    Warrant
       Pre-funded
    Warrant
       Common
    Stock
    Warrant
     
                         
    Balance at January 1, 2025  $847,753   $5,333,794   $12,467,515   $52,682,426   $94,286,790 
    Subtractions   
    -
        
    -
        
    -
        (3,055,814)   
    -
     
    Change in fair value   (567,413)   (3,685,329)   (8,616,568)   (33,535,593)   (58,440,797)
    Ending balance, March 31, 2025  $280,340   $1,648,465   $3,850,947   $16,091,019   $35,845,993 

     

    25

     

     

    NOTE 11 – RELATED PARTY TRANSACTIONS

     

    Advances – related party

     

    Advance to Star: In December 2024, the Company advanced $1,000,000 to Star pursuant to the terms of the Star Agreement (see Note 1). In February 2025, the Company advanced an additional $800,000 to Star pursuant to the first amendment of the Star Agreement, bringing the total amount of the advance made to Star to $1,800,000 as of March 31, 2025. This amount is a short-term, non-interest bearing advance in nature and will be deducted from the total investment consideration upon the closing of the Star Agreement. No interest was imputed due to immateriality. In the event the Star Agreement is not approved, the total amount of the advance will be returned to the Company from Star shortly thereafter.

     

    Due to affiliates : Amounts owed to affiliates totaled $45,078 and $42,471 as of March 31, 2025 and December 31, 2024, respectively. Amounts due to these affiliates are short-term in nature, non-interest bearing, unsecured and repayable on demand.

     

    Loans payable – related parties: The Company has entered into several promissory notes, and made repayments thereon, with shareholders and affiliates (see Note 5).

     

    NOTE 12 – COMMITMENTS AND CONTINGENCIES

     

    Indemnifications: The Company has indemnity agreements with certain officers and directors of the Company pursuant to which the Company must indemnify the officer or director against all expenses, judgments, fines, and amounts paid in settlement reasonably incurred in connection with a third party proceeding, if the indemnitee acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the Company, and in the case of a criminal proceeding, had no reasonable cause to believe the indemnitee’s conduct was unlawful. It is not possible to determine the maximum potential exposure under these indemnification agreements: (i) because the facts and circumstances involved in each claim are unique and the Company cannot predict the number or nature of claims that may be made; (ii) due to the unique facts and circumstances involved in each particular agreement; and (iii) due to the requirement for a registration of the Company’s securities before any of the indemnification obligations contemplated in the IRA become effective.

     

    Legal and regulatory proceedings: The Company is subject to various litigation, regulatory investigations, and other legal proceedings that arise in the ordinary course of its business. The Company is also subject to regulatory oversight by numerous regulatory and other governmental agencies. The Company reviews its lawsuits, regulatory investigations, and other legal proceedings on an ongoing basis and provides disclosure and records loss contingencies in accordance with the loss contingencies accounting guidance. In accordance with such guidance, the Company establishes accruals for such matters when potential losses become probable and can be reasonably estimated. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, the Company discloses the possible loss in the consolidated financial statements.

      

    White lion stock purchase agreement: On May 17, 2022, the Company entered into a Stock Purchase Agreement (the “White Lion Agreement”) with White Lion Capital Partners, LLC a California-based investment fund (“White Lion”). Under the terms of the White Lion Agreement, the Company had the right, but not the obligation, to require White Lion to purchase shares of its common stock up to a maximum amount of $75,000,000. In January 2024, the Company issued 202,702 shares of the Company’s common stock with a fair value of $750,000 to settle its obligation owed under the White Lion Agreement (see Note 8). On February 21, 2024, the Company terminated the White Lion Agreement.

     

    Securities Purchase Agreement: On December 15, 2024, the Company entered into a Securities Purchase Agreement and Call Option, as amended by Amendment No. 1 dated February 11, 2025 (the “Star Agreement”) with Star 26 Capital Inc. (“Star”), the shareholders of Star (“Star Equity Holders”) and an officer of the Company acting in his capacity as the representative of the Star Equity Holders, to acquire a controlling 51% interest in Star, an Israeli corporation engaged as a supplier of generators for “iron dome” launchers and other defense products, in exchange for an aggregate investment of $21,000,000 that consists of :

     

      ● A minimum amount of $5,000,000 in cash

     

    26

     

     

      ● a promissory note in the principal amount of $16,000,000, less (i) the amounts outstanding under Seller Notes, which shall be forgiven and cancelled as of the closing of the transaction, and (ii) any portion of the cash payment to the Sellers in excess of $5,000,000  (the “Investment Note”). The Investment Note matures 12 months following the closing.

     

      ● 2,385,170 shares of the Company’s common stock issued to the Star Equity Holders which shall constitute approximately 29.75% of the issued and outstanding capital of the Company on a fully diluted basis, excluding the out of the money warrants

     

      ● 6,907,859 stock purchase warrants with a five year term and an exercise price of $1.50 per share

     

    The Star Equity Holders granted the Company an option (the “Option”) to purchase the balance of their equity in Star (49.0%) for an aggregate $16,084,250 (the “Option Exercise Price”) in consideration for the issuance to the Star Equity Holders five-year stock purchase warrants to purchase an aggregate of 720,000 shares of the Company’s common stock with an exercise price of $1.50 per share. The Option Exercise Price to be paid by the Company to the Star Equity Holders consists of

     

      ● $3,000,000 in cash,

     

      ● a promissory note in the principal amount of $3,000,000, which accrues interest at 8.0% per annum and is due and payable six months after the issuance thereof,

     

      ● 2,385,170 shares of the Company’s common stock issued to the Star Equity Holders

     

      ● 5,109,789 stock purchase warrants with a five-year term and an exercise price of $1.50 per share

     

    If, for a period of 12 months after the closing of the Star Agreement, the Company’s shares of common stock are delisted from Nasdaq, Star shall have the right, at its own discretion, to require the Company to exchange the Investment Note for all the shares of Star then held by the Company, provided, however, the Option shall be automatically cancelled and Star shall retain any cash payments made by the Company to Star and the Company shall retain an equity interest in Star equivalent to all cash payments. The closing of the Transaction is subject to customary closing conditions, including regulatory approvals, third-party consents, fairness opinion, and approval by the Company’s shareholders as required under applicable Nasdaq listing rules.

     

    If the Star Agreement is canceled because stockholder approval was not obtained within 90-days after the date of the Star Agreement and the failure was a result of the Company failing to perform or observe the covenants or agreements of the Company provided for in the terms of the Star Agreement, the Seller is entitled to damages of $1,800,000 from the Company.

     

    As a result of the Settlement Agreement and subject to the closing of the acquisition of Star, the Company’s business will be focused on the defense sector.

     

    NOTE 13 – SUBSEQUENT EVENTS

     

    The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

     

    The Company established the Nukkleus Inc 2025 Equity Incentive Plan (the “2025 Plan”) to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company by providing them the opportunity to acquire a proprietary interest in the Company and to align their interest and efforts to the long-term interest of the Company’s stockholders. The 2025 Plan will be administered by the Board of Directors and has 1,950,000 shares of the Company’s common stock reserved for issuance. The 2025 Plan is subject to shareholder approval at a meeting schedule during the second quarter of calendar year 2025.

     

    On May 13, 2025, the Company entered into Amendment No. 2 to the Star Agreement. Pursuant to the terms of Amendment No. 2, the cash advances to be made by the Company to Star was increased from $1,800,000 to $3,000,000.

     

    On May 13, 2025, the Company entered into a Promissory Note with Star, pursuant to which the Company memorialized its obligations under the Star Agreement to lend Star up to $3,000,000.

     

    27

     

     

    Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

     

    The following discussion and analysis summarizes the significant factors affecting our financial condition, operating results, liquidity and cash flows as of and for the periods presented below. The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this report. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this report, particularly in the sections titled “Risk Factors” and “Special Note Regarding Forward-Looking Statements.”

     

    Unless the context otherwise requires, references in this “Management’s Discussion and Anlalysis of Financial Condition and Results of Operations” to “Nukkleus”, “we”, “us”, “our”, and the “Company” are intended to refer to (i) following the Business Combination (as defined below), the business and operations of Nukkleus, Inc and its consolidated subsidiaries, and (ii) prior to the Business Combination, Old Nukk (the predecessor entity in existence prior to the consummation of the Business Combination) and its consolidated subsidiaries.

     

    Overview

     

    We are a financial technology company that was historically focused on providing software, technology solutions, customer sales and marketing, and risk management technology hardware and software solutions packages for the worldwide retail foreign exchange (“FX”) trading industry and payment services from one fiat currency to another or to digital assets.

     

    In January 2024, we ceased providing our general support services to customers, terminating our existing customer and supplier contracts with a related party, and shifted our focus to our payment services business. In November 2024, we entered into a Settlement Agreement and Release (the “Settlement Agreement”) with a shareholder and one of our subsidiaries to sell the subsidiary that operates the payment services business to the shareholder in consideration of GBP 1,000 (approximately $1,294 at March 31, 2025).

     

    In December 2024, we entered into a Securities Purchase Agreement and Call Option (the “Star Agreement”) with Star 26 Capital Inc. (“Star”), the shareholders of Star (“Star Equity Holders”) and an officer of Nukkleus, acting in his capacity as the representative of the Star Equity Holders, to acquire a controlling 51% interest in Star, an Israeli corporation engaged as a supplier of generators for “iron dome” launchers and other defense products.

     

    As a result of the Settlement Agreement and subject to the closing of the acquisition of Star, our business will be focused on the defense sector.

     

    Recent Developments

     

    In February 2025, our Board of Directors approved a change in our Company’s fiscal year end from September 30 to December 31 effective for the fiscal year beginning January 1, 2024. The change  resulted in a transition period from October 1, 2024 to December 31, 2024.

     

    Components of Results of Operations

     

    Operating expenses consist of advertising, professional fees, compensation and related benefits, amortization of intangible assets, other general and administrative, and impairment loss.

     

    Professional fees consists of professional services, such as audit fees, legal service fees, advisory fees, and consulting fees., and software subscriptions for support services.

     

    28

     

     

    Compensation and related benefits consists of personnel related expenses incurred in operating our business, including cash compensation and our benefit programs.

     

    Amortization of intangible assets consists of amortization expense recorded on acquired intangible assets with a definite useful life.

     

    Other general and administrative consists of personnel-related expenses incurred to support our business, including executive, customer support, compliance, finance, human resources, legal, and other support operations, and include rent, filing fee, platform fee, travel and entertainment, miscellaneous taxes, and other miscellaneous items.

     

    Other (expense) income, net consists of interest expense, gain (loss) on extinguishment of liabilities, day one loss on issuance of liability-classified stock purchase warrants and embedded derivatives within convertible notes, change in fair value of liability-classified stock purchase warrants and derivative liabilities.

     

    Because these components fluctuate with market conditions, other (expense) income, net can vary widely between periods.

     

    Results of Operations

     

       Three Months Ending
    March 31,
       Changes in 
       2025   2024   Amount   Percentage 
    Operating expenses:                
    Professional fees  $954,142   $1,831,747   $(877,605)   (47.9)%
    Compensation and benefits   63,510    30,000    33,510    111.1%
    Other general and administrative   489,455    223,429    266,026    119.1%
    Impairment loss   -    -    -    - 
    Total operating expenses   1,507,107    2,085,176    (578,069)   (27.7)%
    Other (expense) income, net                    
    Interest expense   (164,576)   —    (164,576)   100.0%
    Interest expense – related parties   (33,841)   (10,025)   (23,816)   237.6%
    Change in fair value – convertible note embedded derivative   567,413    —    567,413    100.0%
    Change in fair value – stock purchase warrant liabilities   104,278,287    —    104,278,287    100.0%
    Other income (expense)   718    —    718    100.0%
    Total other (expense) income, net   104,648,001    (10,025)   104,658,026    1,043,970.3%
    Net income (loss) from continuing operations   103,140,894   $(2,095,201)   105,236,095    (5,022.7)%
    Net loss from discontinued operations   (182,755)   (334,216)   151,461    (45.3)%
    Net income (loss)  $102,958,139   $(2,429,417)  $105,387,556    (4,338.0)%

     

    Comparison For the Three Months Ended March 31, 2025 Versus the Three Months Ended March 31, 2024

     

    Operating Expenses

     

    Professional fees

     

    For the three months ended March 31, 2025, professional fees decreased by approximately $878,000, or 47.9%, as compared to the three months ended March 31, 2024. The significant decrease was primarily attributable to a decrease in advisory service fees of $1,170,000 and legal fees of approximately $222,000, offset by an increase in consulting fees of approximately $388,000 and audit fees of approximately $126,000. This net decrease in professional fees is mainly attributable to the one-time costs incurred in early 2024 in relation to the business combination. We expect that our professional fees will increase in the near future as consultancy agreements were entered into during the fourth quarter with outsourced executives and other personnel of the Company that we anticipate to be in place for the entire fiscal year 2025.

     

    29

     

     

    Compensation and related benefits

     

    For the three months ended March 31, 2025, our compensation and related benefits increased by approximately $34,000, or 111.7%, as compared to the three months ended March 31, 2024. We expect that our compensation and related benefits will increase in the near future if the pending acquisition of Star completes during fiscal year 2025.

     

    Other general and administrative expenses

     

    For the three months ended March 31, 2025, total other general and administrative expenses increased by approximately $266,000, or 119.1%, as compared to the three months ended March 31, 2024. The increase was mainly attributable to additional costs associated with operating as a public company, including an increase in D&O insurance of approximately $128,000, marketing fees of approximately $103,000, rent expenses of approximately $73,000 attributable to new offices established in Israel and New York, entertainment and travel of approximately $29,000 attributable to the travel by our CEO and other business expenses of approximately $60,000, offset by a decrease in filing fees of approximately $127,000. We expect that other general and administrative expenses will increase in the near future if the pending acquisition of Star completes during fiscal year 2025.

     

    Other Income (Expense)

     

    For the three months ended March 31, 2025, other income (expense), net, increased approximately $104,658,000, or 1,043,970.3%, as compared to the three months ended March 31, 2024. The increase was attributable to, an increase in gain from change in fair value – stock purchase warrant liabilities of approximately $104,278,000 andgain from change in fair value – convertible note embedded derivative of approximately $567,000, offset by an increase in interest expense due to amortization of debt discounts of approximately $165,000 and an increase in interest expense on debt-related parties of approximately $24,000.

     

    Discontinued Operations

     

    Net loss from discontinued operations was $182,755 for the three months ended March 31, 2025 compared to $334,216 for the three months ended March 31, 2024. The decrease was due to a decrease in net loss from the operations of the Company’s wholly owed subsidiary DRFQ.

     

    Liquidity and Capital Resources 

     

    We generated a pre-tax net income from continuing operations of $103,140,894 for the three months ended March 31, 2025 and incurred a pre-tax net loss of $2,095,201 for the three months ended March 31, 2024, and have an accumulated deficit of $98,117,604 as of March 31, 2025 and $201,075,743 at December 31, 2024. As of March 31, 2025, we had a working capital deficit of $56,246,392, including $4,462,916 of cash.

     

    We have not been able to generate sufficient cash from operating activities to fund our ongoing operations. Since our inception, we have raised capital through private sales of common stock and debt securities. Our future success is dependent upon our ability to achieve profitable operations and generate cash from operating activities. There is no guarantee that we will be able to generate enough revenue and/or raise capital to support our operations.

     

    To the extent that current and anticipated future sources of liquidity are insufficient to fund our future business activities and cash and other requirements, we may be required to seek additional equity or debt financing. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of additional debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. Even if debt financing is available, the cost of additional financing may be significantly higher than our current debt.

     

    30

     

     

    The risks and uncertainties surrounding the Company’s ability to continue to raise capital and its limited capital resources raise substantial doubt as to the Company’s ability to continue as a going concern for twelve months from the issuance of these consolidated financial statements. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which contemplate our continuation as a going concern.

     

    Cash Flows

     

    The following summarizes the key components of our cash flows for the three months ended March 31, 2025 and 2024:

     

       Three Months Ended
    March 31,
     
       2025   2024 
    Net cash used in operating activities  $(1,341,514)  $(1,122,709)
    Net cash used in investing activities   (810,221)   - 
    Net cash provided by financing activities   -    920,729 
    Effect of exchange rate on cash   32,382    (10,410)
    Net change in cash  $(2,119,353)  $(212,390)

     

    Operating activities

     

    Net cash flow used in operating activities for the three months ended March 31, 2025 was approximately $1,342,000, which primarily reflected our consolidated net income of approximately $102,958,000, adjusted for changes in working capital accounts and certain non-cash income (expenses) of approximately $104,532,000 (including the change in fair value of our liability-classified stock purchase warrants and derivative liabilities of approximately $104,846,000, offset by amortization of debt discount of approximately $135,000, stock-based compensation of approximately $178,000, and depreciation expense of approximately $300).

     

    Net cash flow used in operating activities for the three months ended March 31, 2024 was $1,123,000, which primarily reflected our consolidated net loss of approximately $2,429,000, adjusted for changes in working capital accounts and certain non-cash expense of approximately $75,000 (including stock-based compensation of approximately $75,000).

     

    Investing activities

     

    Net cash flow used in investing activities was approximately $810,221 for the three months ended March 31, 2025, which consisted of an additional advance payment to Star of $800,000 in connection with the plan acquisition of Star, and a purchase of computer equipment of $10,221.

     

    There were no cash flows provided by investing activities for the three months ended March 31, 2024.

     

    Financing activities

     

    There were no cash flows provided by financing activities for the three months ended March 31, 2025.

     

    Net cash flow provided by financing activities was $293,000 for the three months ended March 31, 2024, which consisted of proceeds from loan payable – related parties of $293,000.

     

    31

     

     

    Off-Balance Sheet Arrangements

     

    We had no outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency contracts. We do not engage in trading activities involving non-exchange traded contracts.

     

    Critical Accounting Estimates

     

    Our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q are prepared in accordance with GAAP. The preparation of consolidated financial statements also requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs, and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ significantly from our estimates. To the extent that there are differences between our estimates and actual results, our future financial statement presentation, financial condition, operating results, and cash flows will be affected.

     

    See Note 3. Summary of Significant Accounting Policies of the Notes to our consolidated financial statements included in Part II, Item 8 of this Quarterly Report on Form 10-Q for a summary of significant accounting policies and significant estimates and assumptions and their effects on our financial statements. Below are the significant estimates and assumptions that we consider critical because they involve a significant amount of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations.

     

    Stock-based Compensation

     

    We account for share-based payments that involve the issuance of shares of our common stock to employees and nonemployees and meet the criteria for share-based awards as stock-based compensation expense based on the grant-date fair value of the award. The Company has elected to recognize the adjustment to stock-based compensation expense in the period in which forfeitures occur. We recognize compensation expense for awards with only service conditions on a straight-line basis over the requisite service period for the entire award.

     

    If factors change, and we utilize different assumptions including the probability of achieving performance conditions, share-based compensation cost on future award grants may differ significantly from share-based compensation cost recognized on past award grants. If there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate any remaining unearned share-based compensation cost or incur incremental cost. Share-based compensation cost affects our compensation and benefits expenses.

     

    Warrants

     

    Classification: The Company determines the accounting classification of warrants it issues as either liability or equity classified by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480”), then in accordance with ASC 815-40 (“ASC 815”), Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, the Company assesses the requirements under ASC 815, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815, and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its Common Stock and whether the warrants are classified as equity under ASC 815 or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date.

     

    32

     

     

    We assess the classification of our stock purchase warrants at each reporting date to determine whether a change in classification between equity and liability is required. For modified stock purchase warrants that result in a change of classification from equity to liability, a liability is recognized equal to the fair value on the date of modification, additional paid-in capital is adjusted by the fair value of the warrant on the date of issuance, and the difference is recognized as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss.

     

    Valuation: The fair value of our equity-classified stock purchase warrants and liability-classified stock purchase warrants are determined utilizing Level 3 inputs using a Black-Scholes-Merton option valuation model and a Monte Carlo simulation model, respectively.

     

    In both models, the fair value of an award is affected by our stock price on the date of measurement as well as other assumptions, including the estimated volatility of our stock price over the term of the stock purchase warrant as of the measurement date and the estimated period of time that we expect third parties to hold the stock purchase warrants at the measurement date. The risk-free interest rate assumption we use is based upon United States Treasury interest rates appropriate for the expected life of the stock purchase warrant.

     

    As our stock has limited trading history on NASDAQ, we use the historical volatility of our peer companies in order to estimate future stock price trends. We expect third parties to hold their stock purchase warrants for the contractual term as we do not have any history to support a shorter term and do not anticipate stock purchase warrants to be exercised prior to the end of the term. Our expected dividend rate is zero since we do not currently pay cash dividends on our common stock and do not anticipate doing so in the foreseeable future.

     

    We use the Monte Carlo simulation model for our liability-classified stock purchase warrants in order to incorporate other subjective assumptions based on the terms of the specific stock purchase warrant agreements or the related host contract. For our liability-classified stock purchase warrants as of March 31, 2025, we included the probability of a fundamental event, as defined in the relevant agreements, occurring in our assumptions.

     

    The aforementioned inputs entered into the models we use to fair value our stock purchase warrants are subjective estimates and changes to these estimates will cause the fair value of our stock purchase warrants and related debt issuance discount we recognize to vary.

     

    Derivative Financial Instruments

     

    Classification: We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. Derivative instruments are initially recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss included in this Report under “Item 8. Financial Statements”. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Bifurcated embedded derivatives are classified with the related host contract on the Company’s balance sheet.

     

    33

     

     

    Valuation: We use the Monte Carlo simulation model for our bifurcated embedded derivatives in order to incorporate subjective assumptions based on the terms of the specific host contracts. For our bifurcated embedded derivatives issued in connection with our December 2024 convertible note payable, we included the probability of a fundamental event, as defined in the relevant agreements, occurring in our assumptions in addition to the estimated volatility of our stock price over the term of the bifurcated embedded derivative as of the measurement date, the remaining term of the host contract at the measurement date, the risk-free interest rate based upon United States Treasury interest rates appropriate for the expected term, the conversion discount, and the redemption premium.

     

    Legal and other contingencies

     

    We are subject to various legal proceedings and claims that arise in the ordinary course of business, the outcomes of which are inherently uncertain, and such uncertainty may be enhanced due to the industry in which we operate. We record a liability when it is probable that a loss has been incurred and the amount is reasonably estimable, the determination of which requires significant judgment. In addition, we record recoveries of these losses when it is probable that they will be collected. These estimates are highly sensitive to change and involve variables that are not completely within our control nor practicable to model, including decisions made by regulators and settlement negotiations. Resolution of legal and other contingencies in a manner inconsistent with management’s expectations could have a material impact on our financial condition and results of operations.

     

    Recently Issued Accounting Pronouncements

     

    For information about recently issued accounting standards, refer to Note 3 to our Consolidated Financial Statements appearing elsewhere in this report.

     

    Foreign Currency Risk

     

    Foreign currency transaction risk

     

    Revenues, expenses, and financial results of our foreign subsidiaries are recorded in the functional currency of these subsidiaries. Our foreign currency exposure is primarily related to transactions denominated in British Pounds attributable to cash, customer custodial funds and customer custodial cash liabilities and intercompany transactions where the transaction currency is different from a subsidiary’s functional currency. Changes in foreign exchange rates, and in particular a weakening of foreign currencies relative to the U.S. dollar may negatively affect our results of operations as expressed in U.S. dollars. We have experienced and will continue to experience fluctuations in our results of operations as a result of gains or losses on the settlement and the remeasurement of monetary assets and liabilities denominated in foreign currencies that are not the functional currency of the respective entity.

     

    If an adverse 10% foreign currency exchange rate change was applied to the largest foreign currency exposure (e.g. British Pound) or to all foreign currency exposures in aggregate, of monetary assets, liabilities, and commitments denominated in currencies other than its functional currency as of March 31, 2025 and December 31, 2024, it would not have a material impact on our financial results.

     

    From time to time, we may enter into derivatives or other financial instruments in an attempt to hedge our exposure to foreign currency exchange risk. It is difficult to predict the impact hedging activities would have on our results of operations. Additionally, the volatility of exchange rates depends on many factors that we cannot forecast with reliable accuracy. Our international operations increase our exposure to exchange rate fluctuations and, as a result, such fluctuations could have a material impact on our future results of operations and cash flows.

     

    34

     

     

    Foreign currency translation risk

     

    Fluctuations in functional currencies from our net investment in international subsidiaries expose us to foreign currency translation risk, where changes in foreign currency exchange rates may adversely affect our results of operations upon translation into U.S. dollars. See the consolidated statements of comprehensive income (loss) in Part II, Item 8 of this Quarterly Report on Form 10-Q for translation adjustments for the three months ended March 31, 2025 and 2024, a 10% increase or decrease in foreign currency exchange rates used in translating the financial statements of subsidiaries with functional currencies other than our reporting currency would not have a material impact on our financial results.

     

    Item 3. Quantitative and Qualitative Disclosures about Market Risk

     

    We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

     

    Item 4. Controls and Procedures

     

    Evaluation of Disclosure Controls

     

    Our chief executive officer who also serves as our principal financial officer evaluated the effectiveness of our “disclosure controls and procedures” as of March 31, 2025, the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is accumulated and communicated to a company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our disclosure controls and procedures as of March 31, 2025, our Chief Executive Officer who also serves as our principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective.

     

    Material Weaknesses in Internal Control Over Financial Reporting

     

    A material weakness is defined as a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.

     

    Management identified material weaknesses in the Company’s internal control over financial reporting as of December 31, 2024 related to the Company possessing sufficient resources to properly identify and account for the evaluation of intangible assets and its cost-method investments and to implement and sustain appropriate entity-level controls.

     

    Following the identification and communication of the material weakness described above, management commenced remediation actions relating to this material weakness beginning in the fourth quarter of fiscal year 2024, as follows:

     

      ● We are utilizing the services of external consultants for non-routine and\or technical accounting issues as they arise.

     

      ● We are expanding and improving our review process for complex accounting transactions. We plan to further improve this process by enhancing access to accounting literature, identification of third-party professionals with whom to consult regarding complex accounting applications and consideration of additional staff with the requisite experience and training to supplement existing accounting professionals.

     

      ● We are implementing enhancements and process improvements, including the design and implementation of well-defined controls and related control attributes

     

    35

     

     

    The material weaknesses identified above will not be considered fully remediated until these additional controls and procedures have operated effectively for a sufficient period of time and management has concluded, through testing, that these controls are effective. Our management will monitor the effectiveness of our remediation plans and will make changes management determines to be appropriate. If not remediated, these material weaknesses could result in material misstatements to our annual or interim consolidated financial statements that may not be prevented or detected on a timely basis or result in a delayed filing of required periodic reports. If we are unable to assert that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected, and we could become subject to litigation or investigations by Nasdaq, the SEC, or other regulatory authorities, which could require additional financial and management resources.

     

    As of March 31, 2025, management has performed adequate testing to conclude that the material weakness identified in the prior fiscal year has not been remediated as of March 31, 2025 related to the Company possessing sufficient resources to properly identify and account for the evaluation of intangible assets and its cost-method investments and to implement and sustain appropriate entity-level controls.

     

    Changes in Internal Control Over Financial Reporting

     

    Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

     

    Limitations on Effectiveness of Controls and Procedures

     

    In designing and evaluating the disclosure controls and procedure, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedure relative to their costs.

     

    Item 5. Other

     

    None.

     

    36

     

     

    Part II - Other Information

     

    Item 1. Legal Proceedings

     

    From time to time, we are subject to ordinary routine litigation incidental to our normal business operations. We are not currently a party to any material legal proceedings.

     

    Item 1A. Risk Factors

     

    Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report on Form 10-KT for the period ended December 31, 2024 as filed with the SEC on May 8, 2025 (“Annual Report”). There have been no material changes in our risk factors from those previously disclosed in our Annual Report. You should carefully consider the risks described in our Annual Report which could materially affect our business, financial condition or future results. The risks described in our Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

     

    Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

     

    None.

     

    Item 3. Defaults Upon Senior Securities

     

    None.

     

    Item 4. Mine Safety Disclosures

     

    Not Applicable.

     

    Item 5. Other Information

     

    During the quarter ended March 31, 2025, no director or officer adopted or terminated (i) any contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or (ii) any “non-Rule 10b5-1 trading arrangement” as defined in paragraph (c) of item 408 of Regulation S-K.

     

    37

     

     

    Item 6. Exhibits

     

    The following exhibits are incorporated into this Form 10-Q Quarterly Report:

     

            Incorporated by Reference
    Exhibit   Description   Schedule/
    Form
      Exhibits   Filing Date
    2.1#   Amended and Restated Agreement and Plan of Merger dated as of June 23, 2023, by and among Nukkleus and Brilliant.   Form 8-K   2.1   June 26, 2023
    2.2#   First Amendment to Amended and Restated Agreement and Plan of Merger dated as of November 1, 2023, by and among Nukkleus and Brilliant.   Form 8-K   2.2   November 2, 2023
    3.1   Amended and Restated Certificate of Incorporation of Nukkleus Inc. (f/k/a Brilliant Acquisition Corp.)   Form 8-K   3.2   January 2, 2024
    3.2   Bylaws of Nukkleus Inc.   Form 8-K   3.3   January 2, 2024
    3.3   Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation dated October 11, 2024   Form 8-K   3.1   October 18, 2024
    3.4   Certificate of Correction to the Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation dated October 16, 2024   Form 8-K   3.2   October 18, 2024
    3.5   Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation dated October 18, 2024   Form 8-K   3.3   October 18, 2024
    3.6   Amended and Restated Bylaws   Form 8-K   3.1   November 12, 2024
    4.1   Senior Unsecured Promissory Note dated June 11, 2024 issued to X Group Fund of Funds   Form 8-K   4.1   June 17, 2024
    4.2   Common Stock Purchase Warrant issued to X Group Fund of Funds   Form 8-K   4.2   June 17, 2024
    4.3   Senior Unsecured Promissory Note dated August 1, 2024 issued to East Asia Technology Investments Limited   Form 8-K   4.1   August 5, 2024
    4.4   Common Stock Purchase Warrant issued to East Asia Technology Investments Limited   Form 8-K   4.2   August 5, 2024
    4.5   Form of Senior Unsecured Promissory Note dated September 10, 2024 issued to X Group Fund of Funds   Form 8-K   4.1   September 12, 2024
    4.6   Form of Warrant – December 2024   Form 8-K   4.1   December 20, 2024
    4.7   Form of Pre-Funded Common Stock Purchase Warrant – December 2024   Form 8-K   4.2   December 20, 2024
    4.8   Description of Securities   Form 10-KT   4.8   May 8, 2025
    10.1*   Nukkleus 2023 Incentive Award Plan.   Form 8-K   10.1   January 2, 2024
    10.2   Form of Registration Rights Agreement by and among Nukkleus, Brilliant and certain stockholders.   Form 8-K   10.3   June 26, 2023
    10.3   Form of Lock-Up Agreement by and among Nukkleus, Brilliant and certain stockholders.   Form 8-K   10.2   June 26, 2023
    10.4   General Service Agreement between Nukkleus Limited and FML Malta Limited dated May 24, 2016   Form 10-K   10.4   July 12, 2024
    10.5   General Service Agreement between Nukkleus Limited and FXDirectDealer LLC dated May 24, 2016   Form 10-K   10.5   July 12, 2024
    10.6   Amendment No. 1 dated June 3, 2016 to the General Service Agreement between Nukkleus Limited and FXDD Trading Limited   Form 10-K   10.6   July 12, 2024
    10.7   Amendment dated October 17, 2017 of that certain General Service Agreement between Nukkleus Limited and FML Malta Limited   Form 10-K   10.7   July 12, 2024
    10.8   Letter Agreement entered between FML Malta Ltd., FXDD Malta Limited and Nukkleus Limited   Form 10-K   10.8   July 12, 2024
    10.9   Settlement Agreement and Stipulation dated May 28, 2024 by and between Nukkleus Inc. and Silverback Capital Corporation   Form 8-K   10.1   June 4, 2024
    10.10   Restructuring Agreement dated June 11, 2024 between Nukkleus Inc. and X Group Fund of Funds   Form 8-K   10.1   June 17, 2024
    10.11   Voting Agreement dated June 11, 2024 between Nukkleus Inc. and X Group Fund of Funds   Form 8-K   10.2   June 17, 2024
    10.12   Release Agreement between Nukkleus Inc., Triton Capital Markets Ltd. and FXDirectDealer LLC dated September 30, 2024   Form 8-K   10.3   October 4, 2024
    10.13   Form of Exit and Settlement Agreement dated November 8, 2024   Form 8-K   10.1   November 12, 2024
    10.14   Securities Purchase Agreement dated November 8, 2024   Form 8-K   10.2   November 12, 2024
    10.15   Conversion Agreement entered with X Group Fund of Funds dated November 8, 2024 Settlement Agreement and Release among   Form 8-K   10.3   November 12, 2024

     

    38

     

     

    10.16   Nukkleus Inc., Jamal Khurshid and Match Financial Limited dated November 8, 2024   Form 8-K   10.4   November 12, 2024  
    10.17   Letter Agreement between Nukkleus Inc. and X Group Fund of Funds dated November 14, 2024   Form 8-K   10.1   November 15, 2024
    10.18   Securities Purchase Agreement dated November 19, 2024   Form 8-K   10.1   November 22, 2024
    10.19   Standby Equity Distribution Agreement dated December 3, 2024 between Nukkleus Inc. and YA II PN, Ltd.   Form 8-K   10.1   December 6, 2024
    10.20   Form of Convertible Promissory Notes issued to YA II PN, Ltd.   Form 8-K   10.2   December 6, 2024  
    10.21     Registration Rights Agreement dated December 3, 2024 between Nukkleus Inc. and YA II PN, Ltd.   Form 8-K   10.3   December 6, 2024  
    10.22#   Securities Purchase Agreement and Call between Nukkleus Inc. Star 26 Capital Inc., the shareholders of Star 26 Capital Inc. and the representative of such shareholders, dated December 15, 2024   Form 8-K   10,1   December 17, 2024
    10.23#   Form of Securities Purchase Agreement dated December 18, 2024 between Nukkleus Inc. and the purchasers identified therein   Form 8-K   10.1   December 20, 2024
    10.24   Form of Registration Rights Agreement – December 2024   Form 8-K   10.2   December 20, 2024  
    10.25   Placement Agent Agency Agreement dated December 18, 2024 between Nukkleus Inc. and Dawson James Securities Inc.   Form 8-K   10.3   December 20, 2024  
    10.26   Termination Agreement entered between Nukkleus Inc. and YA II PN Ltd dated December 19, 2024   Form 8-K   10.4   December 20, 2024  
    10.27*   Nukkleus 2024 Incentive Award Plan   Form 10-KT    10.27    May 8, 2025
    10.28   Amendment No. 1 to the Securities Purchase Agreement and Call between Nukkleus Inc. Star 26 Capital Inc., the shareholders of Star 26 Capital Inc. and the representative of such shareholders, dated February 11, 2025   Form 8-K   10.2   February 14, 2025
    10.29   Amendment No. 2 to the Securities Purchase Agreement and Call between Nukkleus Inc. Star 26 Capital Inc., the shareholders of Star 26 Capital Inc. and the representative of such shareholders, dated May 13, 2025   Form 8-K   10.1   May 14, 2025
    14.1   Code of Ethics   Form 10-KT   14.1   May 8, 2025
    19.1   Insider Trading Policy   Form 10-K/A   19.1   April 14, 2025 
    21.1   List of Subsidiaries   Form 10-K   21.1   February 10, 2025
    31.1   Rule 13a-14(a) Certification of the Chief Executive Officer and Principal Financial Officer            
    32.1   Section 1350 Certification of Chief Executive Officer and Principal Financial Officer            
    97.1   Policy for the Recovery of Erroneously Awarded Compensation adopted April 8, 2025   Form 10-K/A    97.1   April 14, 2025 
    99.1   Policy on Granting Equity Awards   Form 10-KT   99.1    May 8, 2025 
    101.INS   Inline XBRL Instance Document.            
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.            
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.            
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.            
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.            
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.            
    104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.            

     

    * Indicates management contract or compensatory plan or arrangement.
    # Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

     

    39

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NUKKLEUS INC.
         
      By: /s/ Menachem Shalom
    Dated: May 23, 2025   Menachem Shalom
        Chief Executive Officer (Principal Executive Officer), and Principal Financial and Accounting Officer and Director

     

     

    40

     

    0001787518 false Q1 --12-31 0001787518 2025-01-01 2025-03-31 0001787518 nukk:CommonStock00001ParValuePerShareMember 2025-01-01 2025-03-31 0001787518 nukk:WarrantsEachWarrantExercisableForOneShareOfCommonStockFor9200PerShareMember 2025-01-01 2025-03-31 0001787518 2025-05-22 0001787518 2025-03-31 0001787518 2024-12-31 0001787518 us-gaap:RelatedPartyMember 2025-03-31 0001787518 us-gaap:RelatedPartyMember 2024-12-31 0001787518 nukk:GeneralSupportServicesMember 2025-01-01 2025-03-31 0001787518 nukk:GeneralSupportServicesMember 2024-01-01 2024-03-31 0001787518 nukk:FinancialServicesMember 2025-01-01 2025-03-31 0001787518 nukk:FinancialServicesMember 2024-01-01 2024-03-31 0001787518 2024-01-01 2024-03-31 0001787518 us-gaap:PreferredStockMember 2024-12-31 0001787518 us-gaap:CommonStockMember 2024-12-31 0001787518 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001787518 us-gaap:RetainedEarningsMember 2024-12-31 0001787518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001787518 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001787518 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001787518 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001787518 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001787518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001787518 us-gaap:PreferredStockMember 2025-03-31 0001787518 us-gaap:CommonStockMember 2025-03-31 0001787518 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001787518 us-gaap:RetainedEarningsMember 2025-03-31 0001787518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001787518 us-gaap:PreferredStockMember 2023-12-31 0001787518 us-gaap:CommonStockMember 2023-12-31 0001787518 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001787518 us-gaap:RetainedEarningsMember 2023-12-31 0001787518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001787518 2023-12-31 0001787518 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001787518 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001787518 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001787518 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001787518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001787518 us-gaap:PreferredStockMember 2024-03-31 0001787518 us-gaap:CommonStockMember 2024-03-31 0001787518 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001787518 us-gaap:RetainedEarningsMember 2024-03-31 0001787518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001787518 2024-03-31 0001787518 nukk:BusinessCombinationMember 2025-01-01 2025-03-31 0001787518 nukk:SecuritiesPurchaseAgreementMember 2024-12-31 0001787518 srt:MinimumMember us-gaap:CommonStockMember 2024-10-24 0001787518 srt:MaximumMember us-gaap:CommonStockMember 2024-10-24 0001787518 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0001787518 us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-03-31 0001787518 us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-03-31 0001787518 nukk:WarrantsToPurchaseCommonStockMember 2025-01-01 2025-03-31 0001787518 nukk:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-03-31 0001787518 us-gaap:SegmentDiscontinuedOperationsMember 2025-03-31 0001787518 us-gaap:SegmentDiscontinuedOperationsMember 2024-12-31 0001787518 nukk:FinancialServicesMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-03-31 0001787518 nukk:FinancialServicesMember us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-03-31 0001787518 us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-03-31 0001787518 us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-03-31 0001787518 us-gaap:SegmentDiscontinuedOperationsMember 2024-03-31 0001787518 nukk:ShareholderTwoThousandTwentyFourLoansMember 2023-10-01 2024-09-30 0001787518 nukk:ShareholderTwoThousandTwentyFourLoansMember nukk:PromissoryNotesMember 2023-10-01 2024-09-30 0001787518 nukk:ShareholderTwoThousandTwentyFourLoansMember 2025-01-01 2025-03-31 0001787518 us-gaap:RelatedPartyMember 2024-12-01 2024-12-31 0001787518 nukk:July2024LoanMember 2024-12-01 2024-12-31 0001787518 nukk:July2024LoanMember 2025-03-31 0001787518 2024-06-01 2024-06-30 0001787518 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001787518 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001787518 nukk:UnpaidInterestMember 2025-01-01 2025-03-31 0001787518 nukk:UnpaidInterestMember 2024-01-01 2024-12-31 0001787518 nukk:OctoberTwoThousandTwentyThreeMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyThreeMember 2025-03-31 0001787518 nukk:JanuaryTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:FebruaryTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:MarchTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:AprilTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:MayTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:JuneTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:JulyTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:AugustTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:SeptemberTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:PromissoryNoteMember 2024-04-30 0001787518 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourWarrantMember 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourLoanMember 2024-04-30 0001787518 us-gaap:WarrantMember 2024-04-01 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputOptionVolatilityMember 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputExpectedTermMember 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourLoanMember 2024-04-01 2024-04-30 0001787518 nukk:AprilTwoThousandTwentyFourWarrantMember 2024-04-01 2024-04-30 0001787518 nukk:AugustTwoThousandTwentyFourNoteMember 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourNoteMember 2024-08-31 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourWarrantMember nukk:SeniorUnsecuredPromissoryNoteMember 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourWarrantMember 2024-08-31 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourWarrantMember us-gaap:MeasurementInputExpectedTermMember 2024-08-31 0001787518 nukk:AugustTwoThousandTwentyFourWarrantMember 2024-08-31 0001787518 nukk:DecemberTwoThousandTwentyFourMember 2024-12-03 0001787518 nukk:DecemberTwoThousandTwentyFourMember 2024-12-03 2024-12-03 0001787518 nukk:DecemberTwoThousandTwentyFourMember 2025-01-01 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001787518 nukk:AmortizationEventMember 2025-01-01 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourMember 2024-12-01 2024-12-31 0001787518 nukk:SeptemberTwoThousandTwentyFourNoteMember 2025-01-01 2025-03-31 0001787518 nukk:AugustTwoThousandTwentyFourNoteMember 2025-03-31 0001787518 nukk:AugustTwoThousandTwentyFourNoteMember 2024-12-31 0001787518 nukk:December2024NoteMember 2025-03-31 0001787518 nukk:December2024NoteMember 2024-12-31 0001787518 2024-12-18 2024-12-18 0001787518 2024-12-18 0001787518 nukk:PrivatePlacementWarrantMember 2024-12-19 0001787518 nukk:PreFundedWarrantMember us-gaap:CommonStockMember 2025-03-31 0001787518 nukk:PrivatePlacementWarrantMember us-gaap:CommonStockMember 2025-03-31 0001787518 nukk:PreFundedWarrantMember 2025-03-31 0001787518 nukk:PrivatePlacementWarrantMember 2025-03-31 0001787518 nukk:PreFundedWarrantMember 2025-02-28 2025-02-28 0001787518 nukk:PrivatePlacementWarrantMember 2025-02-28 2025-02-28 0001787518 us-gaap:RelatedPartyMember us-gaap:CommonStockMember 2025-02-28 2025-02-28 0001787518 us-gaap:RelatedPartyMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001787518 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001787518 nukk:PublicWarrantsMember 2020-06-26 0001787518 nukk:PublicWarrantsMember us-gaap:CommonStockMember 2020-06-26 0001787518 nukk:PublicWarrantsMember 2020-06-26 2020-06-26 0001787518 nukk:PublicWarrantsMember 2025-03-31 0001787518 nukk:PrivateWarrantsMember 2020-06-30 0001787518 nukk:PublicWarrantsMember 2023-12-22 0001787518 nukk:PrivateWarrantsMember 2023-12-22 0001787518 srt:MinimumMember nukk:StockPurchaseWarrantsMember 2025-03-31 0001787518 srt:MaximumMember nukk:StockPurchaseWarrantsMember 2025-03-31 0001787518 us-gaap:ConvertibleNotesPayableMember 2025-03-31 0001787518 nukk:StockOptionsIssuedAndOutstandingMember 2025-03-31 0001787518 us-gaap:WarrantMember 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:PublicAndPrivateWarrantsMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:PublicAndPrivateWarrantsMember 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:AprilTwoThousandTwentyFouWarrantsMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:AprilTwoThousandTwentyFouWarrantsMember 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:JuneTwoThousandTwentyFourWarrantsMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:JuneTwoThousandTwentyFourWarrantsMember 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:AugustTwoThousandtwentyFourWarrantsMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:AugustTwoThousandtwentyFourWarrantsMember 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:NovemberTwoThousandTwentyFourWarrantsMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:NovemberTwoThousandTwentyFourWarrantsMember 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:PreFundedWarrantsMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:PreFundedWarrantsMember 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:PrivatePlacementWarrantMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:PrivatePlacementWarrantMember 2025-03-31 0001787518 srt:MinimumMember us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001787518 srt:MaximumMember us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember 2025-03-31 0001787518 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember nukk:PublicAndPrivateWarrantsMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:PublicAndPrivateWarrantsMember 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:AprilTwoThousandTwentyFouWarrantsMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:AprilTwoThousandTwentyFouWarrantsMember 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:JuneTwoThousandTwentyFourWarrantsMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:JuneTwoThousandTwentyFourWarrantsMember 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:AugustTwoThousandtwentyFourWarrantsMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:AugustTwoThousandtwentyFourWarrantsMember 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:NovemberTwoThousandTwentyFourWarrantsMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:NovemberTwoThousandTwentyFourWarrantsMember 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:PreFundedWarrantsMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:PreFundedWarrantsMember 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:PrivatePlacementWarrantMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember nukk:PrivatePlacementWarrantMember 2024-12-31 0001787518 srt:MinimumMember us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001787518 srt:MaximumMember us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001787518 us-gaap:StockOptionMember 2024-12-31 0001787518 us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001787518 us-gaap:WarrantMember 2024-12-31 0001787518 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001787518 us-gaap:StockOptionMember 2024-11-13 2024-11-13 0001787518 nukk:OldNukkEquityIncentivePlanMember 2025-01-01 2025-03-31 0001787518 nukk:OldNukkEquityIncentivePlanMember 2024-01-01 2024-03-31 0001787518 nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourModificationMember nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-11-30 0001787518 nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourModificationMember nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-11-30 0001787518 nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourModificationMember nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2024-11-30 0001787518 nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourModificationMember nukk:JuneTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-11-30 0001787518 nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourIssuanceMember nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-11-30 0001787518 nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourIssuanceMember nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-11-30 0001787518 nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourIssuanceMember nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2024-11-30 0001787518 nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001787518 nukk:NovemberTwoThousandTwentyFourIssuanceMember nukk:NovemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-11-30 0001787518 nukk:PreFundedWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:PreFundedWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001787518 nukk:PreFundedWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:PreFundedWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001787518 nukk:PreFundedWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:PreFundedWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2024-12-31 0001787518 nukk:PreFundedWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:PreFundedWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001787518 nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001787518 nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001787518 nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2024-12-31 0001787518 nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:DecemberTwoThousandTwentyFourWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001787518 nukk:DecemberTwoThousandTwentyFourWarrantsMember nukk:ProbabilityOfAFundamentalEventMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:DecemberTwoThousandTwentyFourWarrantsMember nukk:ProbabilityOfAFundamentalEventMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputOptionVolatilityMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputOptionVolatilityMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputDiscountRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputDiscountRateMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputDefaultRateMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:EmbeddedDerivativeLiabilityMember us-gaap:MeasurementInputDefaultRateMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember nukk:MeasurementInputRedemptionPremiumMember 2025-03-31 0001787518 nukk:DecemberTwoThousandTwentyFourIssuanceMember nukk:EmbeddedDerivativeLiabilityMember nukk:MeasurementInputRedemptionPremiumMember 2024-12-31 0001787518 us-gaap:FairValueInputsLevel1Member nukk:JuneTwoThousandTwentyFourWarrantMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel2Member nukk:JuneTwoThousandTwentyFourWarrantMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel3Member nukk:JuneTwoThousandTwentyFourWarrantMember 2025-03-31 0001787518 nukk:JuneTwoThousandTwentyFourWarrantMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel1Member nukk:November2024WarrantMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel2Member nukk:November2024WarrantMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel3Member nukk:November2024WarrantMember 2025-03-31 0001787518 nukk:November2024WarrantMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel1Member nukk:PreFundedWarrantLiabilitiesMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel2Member nukk:PreFundedWarrantLiabilitiesMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel3Member nukk:PreFundedWarrantLiabilitiesMember 2025-03-31 0001787518 nukk:PreFundedWarrantLiabilitiesMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel1Member nukk:PrivatePlacementWarrantsMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel2Member nukk:PrivatePlacementWarrantsMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel3Member nukk:PrivatePlacementWarrantsMember 2025-03-31 0001787518 nukk:PrivatePlacementWarrantsMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel1Member nukk:EmbeddedDerivativeLiabilityMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel2Member nukk:EmbeddedDerivativeLiabilityMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel3Member nukk:EmbeddedDerivativeLiabilityMember 2025-03-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember 2025-03-31 0001787518 us-gaap:FairValueInputsLevel1Member 2025-03-31 0001787518 us-gaap:FairValueInputsLevel2Member 2025-03-31 0001787518 us-gaap:FairValueInputsLevel3Member 2025-03-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember 2024-12-31 0001787518 nukk:JuneTwoThousandTwentyFourWarrantMember 2024-12-31 0001787518 nukk:November2024WarrantMember 2024-12-31 0001787518 nukk:PreFundedWarrantMember 2024-12-31 0001787518 nukk:CommonStockWarrantMember 2024-12-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember 2025-01-01 2025-03-31 0001787518 nukk:JuneTwoThousandTwentyFourWarrantMember 2025-01-01 2025-03-31 0001787518 nukk:November2024WarrantMember 2025-01-01 2025-03-31 0001787518 nukk:PreFundedWarrantMember 2025-01-01 2025-03-31 0001787518 nukk:CommonStockWarrantMember 2025-01-01 2025-03-31 0001787518 nukk:EmbeddedDerivativeLiabilityMember 2025-03-31 0001787518 nukk:JuneTwoThousandTwentyFourWarrantMember 2025-03-31 0001787518 nukk:November2024WarrantMember 2025-03-31 0001787518 nukk:CommonStockWarrantMember 2025-03-31 0001787518 us-gaap:RelatedPartyMember 2024-12-31 0001787518 2025-02-01 2025-02-28 0001787518 nukk:WhiteLionStockPurchaseAgreementMember 2022-05-17 2022-05-17 0001787518 nukk:WhiteLionStockPurchaseAgreementMember 2024-01-01 2024-01-31 0001787518 nukk:SecuritiesPurchaseAgreementMember 2024-12-15 0001787518 nukk:SecuritiesPurchaseAgreementMember 2024-12-15 2024-12-15 0001787518 nukk:SecuritiesPurchaseAgreementMember 2025-03-31 0001787518 nukk:SecuritiesPurchaseAgreementMember 2025-01-01 2025-03-31 0001787518 nukk:PromissoryNoteMember nukk:SecuritiesPurchaseAgreementMember 2025-01-01 2025-03-31 0001787518 nukk:SecuritiesPurchaseAgreementMember us-gaap:StockOptionMember 2025-03-31 0001787518 nukk:SecuritiesPurchaseAgreementMember us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001787518 us-gaap:WarrantMember us-gaap:StockOptionMember 2025-03-31 0001787518 us-gaap:StockOptionMember 2025-03-31 0001787518 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001787518 nukk:TwoThousandTwentyFivePlanMember 2025-03-31 0001787518 srt:MinimumMember us-gaap:SubsequentEventMember 2025-05-13 0001787518 srt:MaximumMember us-gaap:SubsequentEventMember 2025-05-13 0001787518 us-gaap:SubsequentEventMember 2025-05-13 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:GBP xbrli:pure nukk:Percentage nukk:Years
    Get the next $NUKK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUKK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NUKK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nukkleus to Present at Two Upcoming Investor Conferences

      NEW YORK, June 2, 2025 /PRNewswire/ -- Nukkleus Inc. (NASDAQ:NUKK), which is pursuing a highly disciplined global M&A strategy in the Aerospace & Defense (A&D) industry, today announced that its management team will be presenting at two upcoming investor conferences. June 4: MicroCap Rodeo Conference (in person event to be held at Sparks Steakhouse in NYC)Nukkleus' main presentation is scheduled for 1:00 pm ET. Investors can access the live presentation via the following link: https://www.webcaster4.com/Webcast/Page/3119/52539. Management will also be available for one-on-one meetings with investors throughout the day.June 5: Maxim Group 2025 Virtual Tech Conference (virtual event)Nukkleus'

      6/2/25 8:30:00 AM ET
      $NUKK
      Professional Services
      Consumer Discretionary
    • Nukkleus Comments on Trump Administration's Further Commitment to Build a "Golden Dome"

      NEW YORK, May 22, 2025 /PRNewswire/ -- Nukkleus Inc. (NASDAQ:NUKK), which is pursuing a highly disciplined global M&A strategy in the Aerospace & Defense (A&D) industry, today commented on the recent announcement by the Trump Administration to invest an initial $25 billion in building a "Golden Dome" missile defense shield. The plan to build a Golden Dome aims to counter growing missile threats from adversaries such as China, Russia, Iran, and North Korea, and protect the entire United States from a broad spectrum of threats, including hypersonic, ballistic, and cruise missiles.   Menny Shalom, Nukkleus CEO commented, "As the world enters a new emerging defense era, geopolitical tensions ar

      5/22/25 4:05:00 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary
    • Market Alert: Silynxcom's Drone Awareness Technology Positioned for Growth as Governments Allocate Billions to Counter-Drone Programs Following Russia-Ukraine "Drone War" Lessons

      After ZenaTech's 600% Surge in November, Could Silynxcom Be the Next Drone-Related Multibagger? Silynxcom's Drone Sounds Awareness Tech Could to Disrupt $11.12 Billion Counter-Drone Market with Wall Street Analysts Maintaining "Buy" Rating and $8 Price Target; Company Successfully Field Tests Key Drone-Awareness Technology as Global Defense Spending Surges to $2.46 Trillion; Israeli Defense Tech Stocks Like Nukkleus with 1000%+ Gains Demonstrate Potential Upside as Militaries Worldwide Ramp Up Spending; $19.1 Billion Tactical Communications Market Seeing Massive Growth Market News Alerts Reports: The escalating drone warfare landscape, dramatically illustrated by Ukraine's innovative use o

      3/21/25 9:01:00 AM ET
      $NUKK
      $SYNX
      $ZENA
      Professional Services
      Consumer Discretionary
      Consumer Electronics/Appliances
      Consumer Staples

    $NUKK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Executive Officer Kotaieva Anastasiia was granted 150,000 shares and bought $771,084 worth of shares (319,952 units at $2.41) (SEC Form 4)

      4/A - Nukkleus Inc. (0001787518) (Issuer)

      12/23/24 8:36:16 AM ET
      $NUKK
      Professional Services
      Consumer Discretionary
    • Chief Executive Officer Kotaieva Anastasiia was granted 500,000 shares and bought $771,084 worth of shares (319,952 units at $2.41) (SEC Form 4)

      4 - Nukkleus Inc. (0001787518) (Issuer)

      12/20/24 4:01:11 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary

    $NUKK
    Leadership Updates

    Live Leadership Updates

    See more
    • Nukkleus Appoints Brigadier General (Ret.) Mark Beesley as Strategic Advisor for Defense Acquisitions

      NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Nukkleus Inc. (NASDAQ:NUKK) is proud to announce the appointment of Brigadier General (Ret.) Mark Beesley as Strategic Advisor to the Board, focusing on defense sector acquisitions. This appointment follows the unanimous approval by the Nukkleus Board of Directors to establish an Advisory Board, demonstrating the company's commitment to leveraging strategic guidance for its growth in key sectors. Mark Beesley: From Military Leadership to Civilian Innovation General Beesley served over three decades in the U.S. Air Force, holding critical

      1/24/25 8:00:00 AM ET
      $NUKK
      Professional Services
      Consumer Discretionary

    $NUKK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nukkleus Inc.

      10-Q - Nukkleus Inc. (0001787518) (Filer)

      5/23/25 4:37:37 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary
    • SEC Form NT 10-Q filed by Nukkleus Inc.

      NT 10-Q - Nukkleus Inc. (0001787518) (Filer)

      5/15/25 4:05:09 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary
    • Amendment: SEC Form S-1/A filed by Nukkleus Inc.

      S-1/A - Nukkleus Inc. (0001787518) (Filer)

      5/15/25 4:01:52 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary

    $NUKK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Executive Officer Kotaieva Anastasiia was granted 150,000 shares and bought $771,084 worth of shares (319,952 units at $2.41) (SEC Form 4)

      4/A - Nukkleus Inc. (0001787518) (Issuer)

      12/23/24 8:36:16 AM ET
      $NUKK
      Professional Services
      Consumer Discretionary
    • Chief Executive Officer Rokach David was granted 10,000 shares (SEC Form 4)

      4 - Nukkleus Inc. (0001787518) (Issuer)

      12/20/24 4:01:15 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary
    • Chief Executive Officer Yeganeh Reuven was granted 10,000 shares (SEC Form 4)

      4 - Nukkleus Inc. (0001787518) (Issuer)

      12/20/24 4:01:10 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary

    $NUKK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nukkleus Inc.

      SC 13G/A - Nukkleus Inc. (0001787518) (Subject)

      11/12/24 1:45:25 PM ET
      $NUKK
      Professional Services
      Consumer Discretionary